Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel risk loci for COVID-19 hospitalization among admixed American populations

  • Diz-de Almeida, Silvia|||0000-0003-2813-8928
  • Cruz, Raquel|||0000-0002-6964-8898
  • Luchessi, Andre D.
  • Lorenzo-Salazar, José M.
  • López de Heredia, Miguel|||0000-0003-2826-9565
  • Quintela, Inés|||0000-0002-0239-7975
  • González-Montelongo, Rafaela
  • Nogueira Silbiger, Vivian|||0000-0002-9252-0278
  • Sevilla Porras, Marta
  • Tenorio Castaño, Jair Antonio|||0000-0002-5308-2316
  • Nevado, Julián|||0000-0001-5611-2659
  • Aguado, José María|||0000-0002-9520-8255
  • Aguilar, Carlos
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • Almadana, Virginia
  • Almoguera, Berta|||0000-0002-5599-2954
  • Alvarez, Nuria
  • Andreu-Bernabeu, Álvaro
  • Arana-Arri, Eunate|||0000-0001-9759-333X
  • Arango, Celso|||0000-0003-3382-4754
  • Arranz, María Jesús|||0000-0002-6757-9198
  • Artiga, Maria-Jesus
  • Baptista-Rosas, Raúl C.|||0000-0002-0273-4740
  • Barreda Sánchez, María
  • Belhassen-Garcia, Moncef
  • Bezerra, Joao F.
  • Bezerra, Marcos AC.
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Brion, María|||0000-0001-7463-2148
  • Brugada, Ramon|||0000-0001-6607-3032
  • Bustos, Matilde
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Carbonell, Cristina|||0000-0002-6271-5111
  • Castaño, Luis|||0000-0003-0437-9401
  • Castelao, Jose E.
  • Conde-Vicente, Rosa
  • Cordero-Lorenzana, M. Lourdes
  • Cortes-Sanchez, Jose L.
  • Corton, Marta|||0000-0003-0087-1626
  • Darnaude, M. Teresa
  • De Martino-Rodríguez, Alba|||0000-0002-2436-9852
  • Campo Pérez, Víctor del|||0000-0002-9424-9653
  • Diaz de Bustamante, Aranzazu
  • Domínguez-Garrido, Elena|||0000-0002-2066-0511
  • Eirós, Rocío
  • Fariñas, M. Carmen
  • Fernandez-Nestosa, María J.|||0000-0001-7764-7791
  • Fernández-Robelo, Uxía
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Gago-Dominguez, Manuela
  • Gil-Fournier, Belén
  • Gómez-Arrue, Javier
  • González Álvarez, Beatriz
  • González Bernaldo de Quirós, Fernan
  • González-Neira, Anna
  • González-Peñas, Javier|||0000-0002-3850-3012
  • Gutiérrez-Bautista, Juan F.|||0000-0003-1374-0756
  • Herrero, María José
  • Herrero-Gonzalez, Antonio
  • Jimenez-Sousa, María A.
  • Lattig, María Claudia|||0000-0003-2113-9266
  • Liger Borja, Anabel
  • Lopez-Rodriguez, Rosario
  • Mancebo, Esther
  • Martín-López, Caridad
  • Martín, Vicente|||0000-0003-0552-2804
  • Martinez-Nieto, Oscar
  • Martinez-Lopez, Iciar
  • Martinez-Resendez, Michel F.
  • Martinez-Perez, Angel|||0000-0002-5934-1454
  • Mazzeu, Juliana F.
  • Merayo Macías, Eleuterio
  • Minguez, Pablo|||0000-0003-4099-9421
  • Moreno Cuerda, Victor
  • Oliveira, Silviene F.|||0000-0002-7741-0257
  • Ortega-Paino, Eva
  • Parellada, Mara|||0000-0001-7977-3601
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Santos, Ney PC.
  • Pérez-Matute, Patricia
  • Perez, Patricia
  • Pérez-Tomás, M. Elena|||0000-0002-5429-3414
  • Perucho, Teresa
  • Pinsach-Abuin, Mellina
  • Pita, Guillermo|||0000-0003-2393-0510
  • Pompa-Mera, Ericka N.
  • Porras-Hurtado, Gloria L.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Ramiro-León, Soraya
  • Resino, Salvador|||0000-0001-8783-0450
  • Fernandes, Marianne R.
  • Rodríguez-Ruiz, Emilio
  • Rodriguez-Artalejo, Fernando
  • Rodriguez-Garcia, José A.
  • Ruiz-Cabello, Francisco
  • Ruiz-Hornillos, Javier
  • Ryan, Pablo|||0000-0002-4212-7419
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
  • Souto, Juan Carlos|||0000-0003-2092-5142
  • Tamayo, Eduardo
  • Tamayo-Velasco, Alvaro
  • Taracido-Fernandez, Juan Carlos
  • Teper, AlejandroHospital de Niños Ricardo Gutierrez (Buenos Aires, Argentina)
  • Torres-Tobar, Lilian
  • Urioste, Miguel|||0000-0001-7583-7305
  • Valencia-Ramos, Juan
  • Yáñez, Zuleima
  • Zarate, Ruth N.
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Sánchez, Pascual
  • Real, Luis M.|||0000-0003-4932-7429
  • Guillén-Navarro, Encarna|||0000-0002-2915-7381
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Parra, Esteban J.|||0000-0002-2057-8577
  • Riancho, José A.|||0000-0003-0691-8755
  • Rojas-Martinez, Augusto|||0000-0003-3765-6778
  • Flores, Carlos|||0000-0001-5352-069X
  • Lapunzina, Pablo|||0000-0002-6324-4825
  • Carracedo, Ángel|||0000-0003-1085-8986
The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific common risk loci. In this second study nested in the SCOURGE consortium, we conducted a genome-wide association study (GWAS) for COVID-19 hospitalization in admixed Americans, comprising a total of 4702 hospitalized cases recruited by SCOURGE and seven other participating studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide significant associations, two of which constitute novel loci and were first discovered in Latin American populations (BAZ2B and DDIAS). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in CREBBP. Finally, we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort. This study constitutes the largest GWAS for COVID-19 hospitalization in admixed Latin Americans conducted to date. This allowed to reveal novel risk loci and emphasize the need of considering the diversity of populations in genomic research.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, A.
  • Taniguchi, M.
  • Saare, L.
  • Särekannu, K.
  • Voyer, T.L.
  • Philippot, Q.
  • Rosain, J.
  • Bizien, L.
  • Asano, T.
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Migaud, M.
  • Tsumura, M.
  • Conti, F.
  • Belot, Alexandre|||0000-0003-4902-5332
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Morio, T.
  • Tanaka, J.
  • Javouhey, E.
  • Haerynck, F.
  • Duvlis, S.
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, S.
  • Tandjaoui-Lambiotte, Y.
  • Escoda, S.
  • Husain, M.
  • Pan-Hammarström, Q.
  • Hammarström, L.
  • Ahlijah, G.
  • Haidar, A.A.
  • Soudee, C.
  • Arseguel, V.
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Sahanic, S.
  • Tancevski, I.
  • Nukui, Y.
  • Hayakawa, S.
  • Chrousos, G.P.
  • Michos, A.
  • Tatsi, E.B.
  • Filippatos, F.
  • Rodriguez-Palmero, A.
  • Troya, Jesús|||0000-0001-7323-114X
  • Tipu, I.
  • Meyts, I.
  • Roussel, L.
  • Ostrowski, S.R.
  • Schidlowski, L.
  • Prando, C.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cheikh, N.
  • Bousfiha, A.A.
  • Bakkouri, J.E.
  • Peterson, P.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Lévy, R.
  • Quartier, P.
  • Vinh, D.C.
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, V.
  • Zhang, S.Y.
  • Borghesi, A.
  • Pession, A.
  • Andreakos, E.
  • Marr, N.
  • Mentis, A.F.A.
  • H.mogensen, T.
  • Rodríguez-Gallego, C.
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Tillmann, V.
  • Neven, B.
  • Trouillet-Assant, S.
  • Brodin, P.
  • Abel, Laurent|||0000-0001-7016-6493
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Zhang, Q.
  • Martinón Torres, Federico|||0000-0002-9023-581X
  • Salas, A.
  • Gómez-Carballa, A.
  • Gonzalez-Granado, L.I.
  • Kisand, K.
  • Okada, S.
  • Puel, A.
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Alkan, G.
  • Castagnoli, R.
  • Cyrus, C.|||0000-0001-7333-6486
  • Bozdemir, S.E.
  • Emiroglu, M.
  • Gulhan, Belgin|||0000-0003-0839-1301
  • Erdeniz, E.H.
  • Hatipoglu, N.
  • Bayhan, G.I.|||0000-0002-1423-4348
  • Jabandziev, P.
  • Yuksek, S.K.
  • Karbuz, A.
  • Öz, Ş.K.T.
  • Marseglia, G.L.
  • Akcan, O.M.
  • Kılıç, A.O.
  • Parlakay, A.O.
  • Papadaki, M.
  • Slaba, K.
  • Sevketoglu, Esra|||0000-0002-8330-2877
  • Valencia-Ramos, J.
  • Yahşi, A.
  • Tuala, C.
  • Urbieta, A.I.D.
  • Esteban, B.D.
  • Santalla, M.J.D.
  • Pérez, C.F.
  • Villaverde, J.F.
  • Rodríguez, C.G.
  • Allut, J.L.G.
  • Vicente, L.G.
  • Vázquez, E.G.
  • Carballa, A.G.
  • Rial, J.G.
  • Barcala, F.J.G.
  • Liñares, B.G.
  • Iglesias, P.L.
  • Massa, B.L.
  • Fuentes, M.L.
  • Franco, M.L.
  • Lago, A.L.
  • Cruz, D.N.D.l
  • Masid, E.N.
  • Devesa, J.B.O.
  • Seco, J.P.
  • Núñez, M.P.
  • Bernal, M.P.D.M.
  • Freixo, H.P.
  • Rodríguez, L.P.
  • Pischedda, S.
  • Romero, M.P.
  • Reino, A.P.
  • Hervella, G.M.P.
  • Verdes, T.Q.
  • Redondo Collazo, Lorenzo|||0000-0002-3521-678X
  • Casuso, P.R.
  • García, S.R.
  • Vázquez, S.R.
  • Blanco, V.R.
  • Calle, I.R.
  • Velasco, C.R.
  • Núñez, N.R.
  • Sánchez, C.R.T.
  • Paz, E.S.
  • Orayyou, J.M.S.
  • Villanueva, C.S.
  • Fernández, S.S.
  • Sanmartín, P.S.
  • Muñiz, M.T.
  • Pena, R.T.
  • Castellano, M.T.
  • Cuadrado, L.V.
  • García, P.V.
  • Iglesias, M.S.V.
  • Lasheras, S.V.
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • Bastón-Rey, I.
  • Calviño-Suárez, C.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Al-Muhsen, S.
  • Al-Mulla, F.
  • Amara, A.
  • Anderson, M.S.
  • Arias, A.A.
  • Arkin, L.M.
  • Feldman, H.B.
  • Biggs, C.M.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bondarenko, A.|||0000-0002-9737-2868
  • Bryceson, Y.
  • Butte, M.J.
  • Casari, G.
  • Christodoulou, J.
  • Constantinescu, S.N.
  • Cooper, M.A.
  • Dalgard, C.L.
  • Desai, M.
  • Drolet, B.A.
  • Duval, X.
  • Baghdadi, J.E.
  • Eloy, P.
  • Espinosa-Padilla, S.
  • Fellay, Jacques|||0000-0002-8240-939X
  • Flores, Carlos|||0000-0001-5352-069X
  • Franco, J.L.
  • Froidure, A.
  • Gorochov, G.
  • Gregersen, P.K.
  • Grimbacher, B.
  • Hagin, D.
  • Halwani, R.
  • Heath, J.R.
  • Hsieh, E.W.Y.
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Imai, K.
  • Itan, Yuval
  • Jarvis, E.D.
  • Kaja, E.
  • Karamitros, T.
  • Ku, C.L.
  • Lau, Y.L.
  • Ling, Y.
  • Lucas, C.L.
  • Mansouri, D.
  • Maródi, L.
  • Mentré, F.
  • Milner, J.D.
  • Mironska, K.
  • Mogensen, T.H.
  • Ng, L.F.P.
  • Notarangelo, L.D.
  • Novelli, A.
  • Novelli, G.
  • O'Farrelly, C.
  • Okamoto, K.
  • Pape, J.W.
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Perez-Tur, J.
  • Perlin, D.S.
  • Pesole, G.
  • Planas, A.M.
  • Quintana-Murci, L.
  • Ramaswamy, S.
  • Renia, L.
  • Resnick, I.
  • Sancho-Shimizu, V.
  • Sediva, A.
  • Seppänen, M.R.J.
  • Shahrooei, M.
  • Shcherbina, A.
  • Slaby, O.
  • Snow, A.L.
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Soumelis, V.
  • Spaan, A.N.
  • Su, H.C.
  • Tangye, S.G.
  • Tayoun, A.A.
  • Temel, Ş.G.
  • Thorball, C.
  • Tiberghien, P.
  • Turvey, S.E.
  • Uddin, K.M.F.
  • Uddin, M.J.
  • Beek, D.v.d
  • Bernuth, H.v
  • Wauters, J.
  • Zatz, Mayana|||0000-0003-3970-8025
  • Zawadzki, Pawel
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

  • Bastard, Paul
  • Rosen, Lindsey B.
  • Zhang, Qian
  • Michailidis, Eleftherios
  • Hoffmann, Hans-Heinrich
  • Zhang, Yu
  • Dorgham, Karim
  • Philippot, Quentin
  • Rosain, Jérémie
  • Béziat, Vivien
  • Manry, Jérémy
  • Kisand, Kai
  • Lionakis, Michail S.
  • Puel, Anne
  • Zhang, Shen-Ying
  • Holland, Steven M.
  • Gorochov, Guy
  • Jouanguy, Emmanuelle
  • Rice, Charles M.
  • Cobat, Aurélie
  • Notarangelo, Luigi D.
  • Abel, Laurent
  • Su, Helen C.
  • Casanova, Jean-Laurent
  • Shaw, Elana
  • Haljasmägi, Liis
  • Peterson, Pärt
  • Lorenzo, Lazaro
  • Bizien, Lucy
  • Trouillet-Assant, Sophie
  • Dobbs, Kerry
  • Almeida de Jesús, Adriana
  • Belot, Alexandre
  • Kallaste, Anne
  • Catherinot, Emilie
  • Tandjaoui-Lambiotte, Yacine
  • Le Pen, Jeremie
  • Kerner, Gaspard
  • Bigio, Benedetta
  • Seeleuthner, Yoann
  • Yang, Rui
  • Bolze, Alexandre
  • Spaan, András N.
  • Delmonte, Ottavia M.
  • Abers, Michael S.
  • Aiuti, Alessandro
  • Casari, Giorgio
  • Lampasona, Vito
  • Piemonti, Lorenzo
  • Ciceri, Fabio
  • Bilguvar, Kaya
  • Lifton, Richard P.
  • Vasse, Marc
  • Smadja, David M.
  • Migaud, Mélanie
  • Hadjadj, Jérome
  • Terrier, Benjamin
  • Duffy, Darragh
  • Quintana-Murci, Lluis
  • Beek, Diederik van der
  • Roussel, Lucie
  • Vinh, Donald C.
  • Tangye, Stuart G.
  • Haerynck, Filomeen
  • Dalmau, David
  • Martínez-Picado, Javier
  • Brodin, Peter
  • Nussenzweig, Michel C.
  • Boisson-Dupuis, Stéphanie
  • Rodríguez-Gallego, Carlos
  • Vogt, Guillaume
  • Mogensen, Trine
  • Oler, Andrew J.
  • Gu, Jingwen
  • Burbelo, Peter D.
  • Cohen, Jeffrey
  • Biondi, Andrea
  • Bettini, Laura Rachele
  • D'Angio, Mariella
  • Bonfanti, Paolo
  • Rossignol, Patrick
  • Mayaux, Julien
  • Rieux-Laucat, Frédéric
  • Husebye, Eystein S.
  • Fusco, Francesca
  • Ursini, Matilde Valeria
  • Imberti, Luisa
  • Sottini, Alessandra
  • Paghera, Simone
  • Quiros-Roldan, Eugenia
  • Rossi, Camillo
  • Castagnoli, Riccardo
  • Montagna, Daniela
  • Licari, Amelia
  • Marseglia, Gian Luigi
  • Duval, Xavier
  • Ghosn, Jade
  • HGID Lab
  • NIAID-USUHS Immune Response to COVID Group
  • COVID Clinicians
  • COVID-STORM Clinicians
  • Imagine COVID Group
  • French COVID Cohort Study Group
  • The Milieu Intérieur Consortium
  • CoV-Contact Cohort
  • Amsterdam UMC Covid-19 Biobank
  • COVID Human Genetic Effort
  • Tsang, John S.
  • Goldbach-Mansky, Raphaela
HGID Lab Andrés Augusto Arias1,3, Bertrand Boisson1,2, Soraya Boucherit2, Jacinta Bustamante1,2, Marwa Chbihi2, Jie Chen1, Maya Chrabieh2, Tatiana Kochetkov1, Tom Le Voyer2, Dana Liu1, Yelena Nemirovskaya1, Masato Ogishi1, Dominick Papandrea1, Cécile Patissier2, Franck Rapaport1, Manon Roynard2, Natasha Vladikine2, Mark Woollett1, Peng Zhang1 1St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University. 2Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children. 3School of Microbiology and Group of Primary Immunodeficiencies, University of Antioquia UdeA, Medellin, Colombia., NIAID-USUHS Immune Response to COVID Group Anuj Kashyap1, Li Ding1, Marita Bosticardo1, Qinlu Wang2, Sebastian Ochoa1, Hui Liu1, Samuel D. Chauvin3, Michael Stack1, Galina Koroleva4, Neha Bansal5, Clifton L. Dalgard6,7, Andrew L. Snow8 1Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. 2Bioinformatics and Computational Biosciences Branch, NIAID Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, USA. 3Laboratory of Immune System Biology, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. 4NIH Center for Human Immunology, NIH, Bethesda, MD, USA. 5Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA. 6PRIMER, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 7Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 8Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA., COVID Clinicians Jorge Abad1, Sergio Aguilera-Albesa2, Ozge Metin Akcan3, Ilad Alavi Darazam4, Juan C. Aldave5, Miquel Alfonso Ramos6, Seyed Alireza Nadji7, Gulsum Alkan8, Jerome Allardet-Servent9, Luis M. Allende10, Laia Alsina11, Marie-Alexandra Alyanakian12, Blanca Amador-Borrero13, Zahir Amoura14, Arnau Antolí15, Sevket Arslan16, Sophie Assant17, Terese Auguet18, Axelle Azot19, Fanny Bajolle20, Aurélie Baldolli21, Maite Ballester22, Hagit Baris Feldman23, Benoit Barrou24, Alexandra Beurton25, Agurtzane Bilbao26, Geraldine Blanchard-Rohner27, Ignacio Blanco1, Adeline Blandinières28, Daniel Blazquez-Gamero29, Marketa Bloomfield30, Mireia Bolivar-Prados31, Raphael Borie32, Ahmed A. Bousfiha33, Claire Bouvattier34, Oksana Boyarchuk35, Maria Rita P. Bueno36, Jacinta Bustamante20, Juan José Cáceres Agra37, Semra Camli38, Ruggero Capra39, Maria Carrabba40, Carlos Casasnovas41, Marion Caseris42, Martin Castelle43, Francesco Castelli44, Martín Castillo de Vera45, Mateus V. Castro36, Emilie Catherinot46, Martin Chalumeau47, Bruno Charbit48, Matthew P. Cheng49, Père Clavé31, Bonaventura Clotet50, Anna Codina51, Fatih Colkesen52, Fatma Colkesen53, Roger Colobran 54, Cloé Comarmond55, Angelo G. Corsico56, David Dalmau57, David Ross Darley58, Nicolas Dauby59, Stéphane Dauger60, Loic de Pontual61, Amin Dehban62, Geoffroy Delplancq63, Alexandre Demoule64, Antonio Di Sabatino65, Jean-Luc Diehl66, Stephanie Dobbelaere67, Sophie Durand68, Waleed Eldars69, Mohamed Elgamal70, Marwa H. Elnagdy71, Melike Emiroglu72, Emine Hafize Erdeniz73, Selma Erol Aytekin74, Romain Euvrard75, Recep Evcen76, Giovanna Fabio40, Laurence Faivre77, Antonin Falck42, Muriel Fartoukh78, Morgane Faure79, Miguel Fernandez Arquero80, Carlos Flores81, Bruno Francois82, Victoria Fumadó83, Francesca Fusco84, Blanca Garcia Solis85, Pascale Gaussem86, Juana Gil-Herrera87, Laurent Gilardin88, Monica Girona Alarcon89, Mónica Girona-Alarcón89, Jean-Christophe Goffard90, Funda Gok91, Rafaela González-Montelongo92, Antoine Guerder93, Yahya Gul94, Sukru Nail Guner94, Marta Gut95, Jérôme Hadjadj96, Filomeen Haerynck97, Rabih Halwani98, Lennart Hammarström99, Nevin Hatipoglu100, Elisa Hernandez-Brito101, María Soledad Holanda-Peña102, Juan Pablo Horcajada103, Sami Hraiech104, Linda Humbert105, Alejandro D. Iglesias106, Antonio Íñigo-Campos92, Matthieu Jamme107, María Jesús Arranz108, Iolanda Jordan109, Fikret Kanat110, Hasan Kapakli111, Iskender Kara112, Adem Karbuz113, Kadriye Kart Yasar114, Sevgi Keles115, Yasemin Kendir Demirkol116, Adam Klocperk117, Zbigniew J. Król118, Paul Kuentz119, Yat Wah M. Kwan120, Jean-Christophe Lagier121, Yu-Lung Lau122, Fleur Le Bourgeois60, Yee-Sin Leo123, Rafael Leon Lopez124, Daniel Leung122, Michael Levin125, Michael Levy60, Romain Lévy20, Zhi Li48, Agnes Linglart126, José M. Lorenzo-Salazar92, Céline Louapre127, Catherine Lubetzki127, Charles-Edouard Luyt128, David C. Lye129, Davood Mansouri130, Majid Marjani131, Jesus Marquez Pereira132, Andrea Martin133, David Martínez Pueyo134, Javier Martinez-Picado135, Iciar Marzana136, Alexis Mathian14, Larissa R. B. Matos36, Gail V. Matthews137, Julien Mayaux138, Jean-Louis Mège139, Isabelle Melki140, Jean-François Meritet141, Ozge Metin142, Isabelle Meyts143, Mehdi Mezidi144, Isabelle Migeotte145, Maude Millereux146, Tristan Mirault147, Clotilde Mircher68, Mehdi Mirsaeidi148, Abián Montesdeoca Melián149, Antonio Morales Martinez150, Pierre Morange151, Demence Mordacq105, Guillaume Morelle152, Stéphane Mouly13, Adrián Muñoz-Barrera92, Cyril Nafati153, João Farela Neves154, Lisa F. P. Ng155, Yeray Novoa Medina156, Esmeralda Nuñez Cuadros157, J. Gonzalo Ocejo-Vinyals158, Zerrin Orbak159, Mehdi Oualha20, Tayfun Özçelik160, Qiang Pan Hammarström161, Christophe Parizot138, Tiffany Pascreau162, Estela Paz-Artal163, Sandra Pellegrini48, Rebeca Pérez de Diego85, Aurélien Philippe164, Quentin Philippot78, Laura Planas-Serra165, Dominique Ploin166, Julien Poissy167, Géraldine Poncelet42, Marie Pouletty168, Paul Quentric138, Didier Raoult139, Anne-Sophie Rebillat68, Ismail Reisli169, Pilar Ricart170, Jean-Christophe Richard171, Nadia Rivet28, Jacques G. Rivière172, Gemma Rocamora Blanch15, Carlos Rodrigo1, Carlos Rodriguez-Gallego173, Agustí Rodríguez-Palmero174, Carolina Soledad Romero175, Anya Rothenbuhler176, Flore Rozenberg177, Maria Yolanda Ruiz del Prado178, Joan Sabater Riera15, Oliver Sanchez179, Silvia Sánchez-Ramón180, Agatha Schluter165, Matthieu Schmidt181, Cyril E. Schweitzer182, Francesco Scolari183, Anna Sediva184, Luis M. Seijo185, Damien Sene13, Sevtap Senoglu114, Mikko Seppänen186, Alex Serra Ilovich187, Mohammad Shahrooei62, David Smadja188, Ali Sobh189, Xavier Solanich Moreno15, Jordi Solé-Violán190, Catherine Soler191, Pere Soler-Palacín133, Yuri Stepanovskiy192, Annabelle Stoclin193, Fabio Taccone145, Yacine Tandjaoui-Lambiotte194, Jean-Luc Taupin195, Simon J. Tavernier196, Benjamin Terrier197, Caroline Thumerelle105, Gabriele Tomasoni198, Julie Toubiana47, Josep Trenado Alvarez199, Sophie Trouillet-Assant200, Jesús Troya201, Alessandra Tucci202, Matilde Valeria Ursini‬84, Yurdagul Uzunhan203, Pierre Vabres204, Juan Valencia-Ramos205, Ana Maria Van Den Rym85, Isabelle Vandernoot206, Hulya Vatansev207, Valentina Vélez-Santamaria41, Sébastien Viel166, Cédric Vilain208, Marie E. Vilaire68, Audrey Vincent34, Guillaume Voiriot209, Fanny Vuotto105, Alper Yosunkaya91, Barnaby E. Young123, Fatih Yucel210, Faiez Zannad211, Mayana Zatz36, Alexandre Belot212* 1University Hospital and Research Institute “Germans Trias i Pujol”, Badalona, Spain. 2Navarra Health Service Hospital, Pamplona, Spain. 3Division of Pediatric Infectious Diseases, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 4Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru. 6Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat Spain. 7Virology Research Center, National institutes of Tuberculosis and Lung diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 8Division of Pediatric Infectious Diseases, Faculty of Medicine, Selcuk University, Konya, Turkey. 9Intensive care unit, Hôpital Européen, Marseille, France. 10Immunology Department, University Hospital 12 de Octubre. Research Institute imas12. Complutense University, Madrid, Spain. 11Hospital Sant Joan de Déu, Barcelona, Spain. 12Department of Biological Immunology, Necker Hospital for Sick Children, APHP and INEM, Paris, France. 13Internal medicine department, Hôpital Lariboisière, APHP; Université de Paris, Paris, France. 14Internal medicine department, Pitié-Salpétrière Hospital, Paris, France. 15Hospital Universitari de Bellvitge, Barcelona, Spain. 16Division of Clinical Immunology and Allergy, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 17Joint Research Unit, Hospices Civils de Lyon-bio Mérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France. 18Hospital U. de Tarragona Joan XXIII. Universitat Rovira i Virgili (URV). IISPV, Tarragona, Spain. 19Private practice, Paris, France. 20Necker Hospital for Sick Children, AP-HP, Paris, France. 21Department of Infectious Diseases, CHU de Caen, Caen, France. 22Consorcio Hospital General Universitario, Valencia, Spain. 23The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 24Dept Urology, Nephrology, Transplantation, APHP-SU, Sorbonne Université, INSERM U 1082, Paris, France. 25Service de Médecine Intensive–Réanimation et Pneumologie, APHP Hôpital Pitié–Salpêtrière, Paris, France. 26Cruces University Hospital, Bizkaia, Spain. 27Paediatric Immunology and Vaccinology Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. 28Hematology, Georges Pompidou Hospital, APHP, Paris, France. 29Pediatric Infectious Diseases Unit. Instituto de Investigación 12 de Octubre (imas12). Hospital Universitario 12 de Octubre, Madrid, Spain. 30Department of Immunology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Department of Pediatrics, Thomayer’s Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. 31Centro de Investigación Biomédica en Red de Enfermedades Hepàticas y Digestivas (Ciberehd). Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Spain. 32Service de Pneumologie, Hopital Bichat, APHP, Paris, France. 33Clinical immunology unit, pediatric infectious disease departement, Faculty of Medicine and Pharmacy, Averroes University Hospital. LICIA Laboratoire d'immunologie clinique, d'inflammation et d'allergie, Hassann Ii University, Casablanca, Morocco. 34Endocrinology unit, APHP Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France. 35Department of Children's Diseases and Pediatric Surgery, I.Horbachevsky Ternopil National Medical University, Ternopil, Ukraine. 36Human Genome and stem-cell research center- University of São Paulo, São Paulo, Brazil. 37Hospital Insular, Las Palmas de Gran Canaria, Spain. 38Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Konya State Hospital, Konya, Turkey. 39MS Center, Spedali Civili, Brescia, Italy. 40Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 41Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. 42Hopital Robert Debré, Paris, France. 43Pediatric Immuno-hematology Unit, Necker Enfants Malades Hospital, AP-HP, Paris, France. 44Department of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. 45Doctoral Health Care Center, Canarian Health System, Las Palmas de Gran Canaria, Spain. 46Hôpital Foch, Suresnes, France. 47Necker Hospital for Sick Children, Paris University, AP-HP, Paris, France. 48Pasteur Institute, Paris, France. 49McGill University Health Centre, Montreal, Canada. 50University Hospital and Research Institute “Germans Trias i Pujol”, IrsiCaixa AIDS Research Institute, UVic-UCC, Badalona, Spain. 51Clinical Biochemistry, Pathology, Paediatric Neurology and Molecular Medicine Departments and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER-ISCIII, Esplugues, Spain. 52Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 53Department of Infectious Diseases and Clinical Microbiology, Konya Training and Research Hospital, Konya, Turkey. 54Hospital Universitari Vall d’Hebron, Barcelona, Spain. 55Pitié-Salpêtrière Hospital, Paris, France. 56Respiratory Diseases Division, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy. 57Fundació Docència i Recerca Mútua Terrassa, Barcelona, Spain. 58UNSW Medicine, St Vincent's Clinical School; Department of Thoracic Medicine, St Vincent's Hospital Darlinghurst, Sidney, Australia. 59CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium. 60Pediatric Intensive Care Unit, Robert-Debré University Hospital, APHP, Paris, France. 61Sorbonne Paris Nord, Hôpital Jean Verdier, APHP, Bondy, France. 62Specialized Immunology Laboratory of Dr. Shahrooei, Sina Medical Complex, Ahvaz, Iran. 63Centre de génétique humaine, CHU Besançon, Besançon, France. 64Sorbonne Université médecine and APHP Sorbonne université site Pitié-Salpêtrière, Paris, France. 65Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. 66Intensive Care unit, Georges Pompidou Hospital, APHP, Paris, France. 67Department of Pneumology, AZ Delta, Roeselare, Belgium. 68Institut Jérôme Lejeune, Paris, France. 69Department of Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 70Department of Chest, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 71Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 72Faculty of Medicine, Division of Pediatric Infectious Diseases, Selcuk University, Konya, Turkey. 73Division of Pediatric Infectious Diseases, Ondokuz Mayıs University, Samsun, Turkey. 74Necmettin Erbakan University, Meram Medical Faculty, Division of Pediatric Allergy and Immunology, Konya, Turkey. 75Centre Hospitalier Fleyriat, Bourg-en-Bresse, France. 76Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 77Centre de Génétique, CHU Dijon, Dijon, France. 78APHP Tenon Hospital, Paris, France. 79Sorbonne Universités, UPMC University of Paris, Paris, France. 80Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, Spain. 81Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain; Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, San Cristóbal de La Laguna, Spain. 82CHU Limoges and Inserm CIC 1435 & UMR 1092, Limoges, France. 83Infectious Diseases Unit, Department of Pediatrics, Hospital Sant Joan de Déu, Barcelona, Spain; Institut de Recerca Sant Joan de Déu, Spain; Universitat de Barcelona (UB), Barcelona, Spain. 84Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’, IGB-CNR, Naples, Italy. 85Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, La Paz Hospital, Madrid, Spain. 86Hematology, APHP, Hopital Européen Georges Pompidou and Inserm UMR-S1140, Paris, France. 87Hospital General Universitario and Instituto de Investigación Sanitaria "Gregorio Marañón", Madrid, Spain. 88Bégin military Hospital, Bégin, France. 89Pediatric Intensive Care Unit, Hospital Sant Joan de Déu, Barcelona, Spain. 90Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 91Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 92Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain. 93Assistance Publique Hôpitaux de Paris, Paris, France. 94Division of Allergy and Immunology, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 95CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST); Universitat Pompeu Fabra (UPF), Barcelona, Spain. 96Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France. 97Ghent University Hospital, Ghent, Belgium. 98Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, UAE. 99Department of Biosciences and Nutrition, SE14183, Huddinge, Karolinska Institutet, Stockholm, Sweden. 100Pediatric Infectious Diseases Unit, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. 101Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain. 102IntensivenCare Unit. Marqués de Valdecilla Hospital, Santander, Spain. 103Hospital del Mar, Parc de Salut Mar, Barcelona, Spain. 104Intensive care unit, APHM, Marseille, France. 105CHU Lille, Lille, France. 106Department of Pediatrics, Columbia University, New York, NY, USA. 107Centre hospitalier intercommunal Poissy Saint Germain en Laye, Poissy, France. 108Division of Respiratory Diseases, Fundació Docència i Recerca Mútua Terrassa, Barcelona, Spain. 109Hospital Sant Joan de Déu, Kids Corona Platfform, Barcelona, Spain. 110Selcuk University, Faculty of Medicine, Chest Diseases Department, Konya, Turkey. 111Division of Allergy and Immunology, Balikesir Ataturk City Hospital, Balikesir, Turkey. 112Division of Critical Care Medicine, Selcuk University, Faculty of Medicine, Konya, Turkey. 113Division of Pediatric Infectious Diseases, Prof. Dr. Cemil Tascıoglu City Hospital, Istanbul, Turkey. 114Departments of Infectious Diseases and Clinical Microbiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. 115Meram Medical Faculty, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 116Health Sciences University, Umraniye Education and Research Hospital, Istanbul, Turkey. 117Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, Prague, Czech Republic. 118Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Warsaw, Poland. 119Oncobiologie Génétique Bioinformatique, PC Bio, CHU Besançon, Besançon, France. 120Paediatric Infectious Disease Unit, Hospital Authority Infectious Disease Center, Princess Margaret Hospital, Hong Kong (Special Administrative Region), China. 121Aix Marseille Univ, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France. 122Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China. 123National Centre for Infectious Diseases, Singapore. 124Hospital Universitario Reina Sofía, Cordoba, Spain. 125Imperial College, London, England. 126Endocrinology and diabetes for children, AP-HP, Bicêtre Paris-Saclay hospital, Le Kremlin-Bicêtre, France. 127Neurology unit, APHP Pitié-Salpêtrière Hospital, Paris University, Paris, France. 128Intensive care unit, APHP Pitié-Salpêtrière Hospital, Paris University, Paris, France. 129National Centre for Infectious Diseases; Tan Tock Seng Hospital; Yong Loo Lin School of Medicine; Lee Kong Chian School of Medicine, Singapore. 130Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 131Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. 132Hospital Sant Joan de Déu and University of Barcelona, Barcelona, Spain. 133Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall d'Hebron Research Institute, Vall d’Hebron Barcelona Hospital Campus. Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 134Hospital Universitari Mutua de Terrassa, Universitat de Barcelona, Barcelona, Spain. 135IrsiCaixa AIDS Research Institute, ICREA, UVic-UCC, Research Institute “Germans Trias i Pujol”, Badalona, Spain. 136Department of Laboratory, Cruces University Hospital, Barakaldo, Bizkaia, Spain. 137University of New South Wales, Australia. 138APHP Pitié-Salpêtrière Hospital, Paris, France. 139Aix-Marseille University, APHM, Marseille, France. 140Robert Debré Hospital, Paris, France. 141APHP Cohin Hospital, Paris, France. 142Necmettin Erbakan University Meram Faculty of Medicine Department of Pediatric Infectious Diseases, Konya, Turkey. 143University Hospitals Leuven, Leuven, Belgium. 144Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France. 145Hôpital Erasme, Brussels, Belgium. 146CH Gonesse, Gonesse, France. 147Vascular Medicine, Georges Pompidou Hospital, APHP, Paris, France. 148Division of Pulmonary and Critical Care, University of Miami, Miami, USA. 149Guanarteme Health Care Center, Canarian Health System, Las Palmas de Gran Canaria, Spain. 150Regional University Hospital of Malaga, Malaga, Spain. 151Aix-Marseille Université, Marseille, France. 152Department of General Paediatrics, Hôpital Bicêtre, AP-HP, University of Paris Saclay, Le Kremlin-Bicêtre, France. 153CHU de La Timone, Marseille, France. 154Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal. 155Infectious Diseases Horizontal Technlogy Centre, A*STAR; Singapore Immunology Network, A*STAR, Singapore. 156Department of Pediatrics, Complejo Hospitalario Universitario Insular-Materno Infantil, Canarian Health System, Las Palmas de Gran Canaria, Spain. 157Regional Universitary Hospital of Malaga, Málaga, Spain. 158Hospital Universitario Marqués de Valdecilla, Santander, Spain. 159Ataturk University Medical Faculty, Erzurum, Turkey. 160Bilkent University, Department of Molecular Biology and Genetics, Ankara, Turkey. 161Department of Laboratory Medicine, Karolinska Institutet, SE14186, Stockholm, Sweden. 162L'Hôpital Foch, Suresnes, France. 163Department of Immunology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. 164APHP Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France. 165Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran i Reynals, Barcelona; CIBERER U759, ISCiii Madrid, Spain. 166Hospices Civils de Lyon, Lyon, France. 167Université de Lille, Inserm U1285, CHU Lille, Paris, France. 168Departement of General Pediatrics, University Hospital Robert Debré, APHP, Paris, France. 169Necmettin Erbakan University, Konya, Turkey. 170Germans Trias i Pujol Hospital, Badalona, Spain. 171Medical intensive care unit. Hopital de la Croix-Rousse. Hospices Civils de Lyon, Lyon, France. 172Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall d'Hebron Research Institute, Vall d’Hebron Barcelona Hospital Campus., Barcelona, Spain. 173Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain, EU. University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain. 174Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran i Reynals, Barcelona, Spain. 175Consorcio Hospital General Universitario, Valencia, Spain. 176APHP Hôpitaux Universitaires Paris-Sud, Paris, France. 177Virology unit, Université de Paris, Cohin Hospital, APHP, Paris, France. 178Hospital San Pedro, Logroño, Spain. 179Respiratory medicine, Georges Pompidou Hospital, APHP, Paris, France. 180Dept. Immunology, Hospital Clínico San Carlos, Madrid, Spain. 181Service de Médecine Intensive Réanimation, Institut de Cardiologie, Hopital Pitié-Salpêtrière, Paris, France. 182CHRU de Nancy, Hôpital d'Enfants, Vandoeuvre, France. 183Chair of Nephrology, University of Brescia, Brescia, Italy. 184Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. 185Clínica Universidad de Navarra, Madrid, Spain. 186HUS Helsinki University Hospital, Children and Adolescents, Rare Disease Center, and Inflammation Center, Adult Immunodeficiency Unit, Majakka, Helsinki, Finland. 187Fundació Docència i Recerca Mútua Terrassa, Terrassa, Spain. 188Hopital Européen Georges Pompidou, Paris, France. 189Department of Pediatrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 190Critical Care Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain. 191CHU de Saint Etienne, Saint-Priest-en-Jarez, France. 192Shupyk National Medical Academy for Postgraduate Education, Kiev, Ukraine. 193Gustave Roussy Cancer Campus, Villejuif, France. 194Intensive Care Unit, Avicenne Hospital, APHP, Bobigny, France. 195Laboratory of Immunology and Histocompatibility, Saint-Louis Hospital, Paris University, Paris, France. 196Department of Internal Diseases and Pediatrics, Primary Immune Deficiency Research Lab, Centre for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium. 197Department of Internal Medicine, Université de Paris, INSERM, U970, PARCC, F-75015, Paris, France. 198First Division of Anesthesiology and Critical Care Medicine, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. 199Intensive Care Department, Hospital Universitari MutuaTerrassa, Universitat Barcelona, Terrassa, Spain. 200Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France. 201Infanta Leonor University Hospital, Madrid, Spain. 202Hematology Department, ASST Spedali Civili di Brescia, Brescia, Italy. 203Pneumologie, Hôpital Avicenne, APHP, INSERM U1272, Université Sorbonne Paris Nord, Bobigny, France. 204Dermatology unit, Laboratoire GAD, INSERM UMR1231 LNC, université de Bourgogne, Dijon, France. 205University Hospital of Burgos, Burgos, Spain. 206Center of Human Genetics, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 207Department of Chest Diseases, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey. 208CHU de Caen, Caen, France. 209Sorbonne Université, Service de Médecine Intensive Réanimation, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France. 210General Intensive Care Unit, Konya Training and Research Hospital, Konya, Turkey. 211CHU de Nancy, Nancy, France. 212University of Lyon, CIRI, INSERM U1111, National referee centre RAISE, Pediatric Rheumatology, HFME, Hospices Civils de Lyon, Lyon, France. *Leader of the COVID-clinicians group., COVID-STORM Clinicians Giuseppe Foti1, Giacomo Bellani1, Giuseppe Citerio1, Ernesto Contro1, Alberto Pesci2, Maria Grazia Valsecchi3, Marina Cazzaniga4 1Department of Emergency, Anesthesia and Intensive Care, School of Medicine and Surgery, University of Milano-Bicocca, San Gerardo Hospital, Monza IT. 2Department of Pneumology, School of Medicine and Surgery, University of Milano-Bicocca, San Gerardo Hospital, Monza IT. 3Center of Bioinformatics and Biostatistics, School of Medicine and Surgery, University of Milano-Bicocca, San Gerardo Hospital, Monza IT. 4Phase I Research Center, School of Medicine and Surgery, University of Milano-Bicocca, San Gerardo Hospital, Monza IT., Imagine COVID Group Christine Bole-Feysot1, Stanislas Lyonnet1*, Cécile Masson1, Patrick Nitschke1, Aurore Pouliet1, Yoann Schmitt1, Frederic Tores1, Mohammed Zarhrate1 1Imagine Institute, Université de Paris, INSERM UMR 1163, Paris, France. *Leader of the Imagine COVID group., French COVID Cohort Study Group Laurent Abel1, Claire Andrejak2, François Angoulvant3, Delphine Bachelet4, Romain Basmaci5, Sylvie Behillil6, Marine Beluze7, Dehbia Benkerrou8, Krishna Bhavsar4, François Bompart9, Lila Bouadma4, Maude Bouscambert10, Mireille Caralp11, Minerva Cervantes-Gonzalez12, Anissa Chair4, Alexandra Coelho13, Camille Couffignal4, Sandrine Couffin-Cardiergues14, Eric D’ortenzio12, Charlene Da Silveira4, Marie-Pierre Debray4, Dominique Deplanque15, Diane Descamps16, Mathilde Desvallées17, Alpha Diallo18, Alphonsine Diouf13, Céline Dorival8, François Dubos19, Xavier Duval4, Philippine Eloy4, Vincent V. E. Enouf20, Hélène Esperou21, Marina Esposito-Farese4, Manuel Etienne22, Nadia Ettalhaoui4, Nathalie Gault4, Alexandre Gaymard10, Jade Ghosn4, Tristan Gigante23, Isabelle Gorenne4, Jérémie Guedj24, Alexandre Hoctin13, Isabelle Hoffmann4, Salma Jaafoura21, Ouifiya Kafif4, Florentia Kaguelidou25, Sabina Kali4, Antoine Khalil4, Coralie Khan17, Cédric Laouénan4, Samira Laribi4, Minh Le4, Quentin Le Hingrat4, Soizic Le Mestre18, Hervé Le Nagard24, François-Xavier Lescure4, Yves Lévy26, Claire Levy-Marchal27, Bruno Lina10, Guillaume Lingas24, Jean Christophe Lucet4, Denis Malvy28, Marina Mambert13, France Mentré4, Noémie Mercier18, Amina Meziane8, Hugo Mouquet20, Jimmy Mullaert4, Nadège Neant24, Marion Noret29, Justine Pages30, Aurélie Papadopoulos21, Christelle Paul18, Nathan Peiffer-Smadja4, Ventzislava Petrov-Sanchez18, Gilles Peytavin4, Olivier Picone31, Oriane Puéchal12, Manuel Rosa-Calatrava10, Bénédicte Rossignol23, Patrick Rossignol32, Carine Roy4, Marion Schneider4, Caroline Semaille12, Nassima Si Mohammed4, Lysa Tagherset4, Coralie Tardivon4, Marie-Capucine Tellier4, François Téoulé8, Olivier Terrier10, Jean-François Timsit4, Théo Treoux4, Christelle Tual33, Sarah Tubiana4, Sylvie van der Werf34, Noémie Vanel35, Aurélie Veislinger33, Benoit Visseaux16, Aurélie Wiedemann26, Yazdan Yazdanpanah36 1Inserm UMR 1163, Paris, France. 2CHU Amiens, France. 3Hôpital Necker, Paris, France. 4Hôpital Bichat, Paris, France. 5Hôpital Louis Mourrier, Colombes, France. 6Institut Pasteur, Paris, France. 7F-CRIN Partners Platform, AP-HP, Université de Paris, Paris, France. 8Inserm UMR 1136, Paris, France. 9Drugs for Neglected Diseases initiative, Geneva, Switzerland. 10Inserm UMR 1111, Lyon, France. 11Inserm Transfert, Paris, France. 12REACTing, Paris, France. 13Inserm UMR 1018, Paris, France. 14Inserm, Pôle Recherche Clinique, France. 15CIC 1403 Inserm-CHU Lille, Paris, France. 16Université de Paris, IAME, INSERM UMR 1137, AP-HP, University hospital Bichat Claude Bernard, Virology, F-75018 Paris, France. 17Inserm UMR 1219, Bordeaux, France. 18ANRS, Paris, France. 19CHU Lille, France. 20Pasteur Institute, Paris, France. 21Inserm sponsor, Paris, France. 22Rouen - SMIT, France. 23FCRIN INI-CRCT, Nancy, France. 24Inserm UMR 1137, Paris, France. 25Centre d'Investigation Clinique, Inserm CIC1426, Hôpital Robert Debré, Paris, France. 26Inserm UMR 955, Créteil, France; Vaccine Research Instiute (VRI), Paris, France. 27F-CRIN INI-CRCT, Paris, France. 28Bordeaux - SMIT, France. 29RENARCI, Annecy, France. 30Hôpital Robert Debré, Paris, France. 31Colombes - Louis Mourier - Gynécologie, France. 32University of Lorraine, Plurithematic Clinical Investigation Centre Inserm CIC-P; 1433, Inserm U1116, CHRU Nancy Hopitaux de Brabois, F-CRIN INI-CRCT; (Cardiovascular and Renal Clinical Trialists), Nancy, France. 33Inserm CIC-1414, Rennes, France. 34Institut Pasteur, UMR 3569 CNRS, Université de Paris, Paris, France. 35hôpital la timone, Marseille, France. 36Paris - Bichat - SMIT, France., The Milieu Intérieur Consortium Laurent Abel1, Andres Alcover2, Hugues Aschard2, Kalla Astrom3, Philippe Bousso2, Pierre Bruhns2, Ana Cumano2, Caroline Demangel2, Ludovic Deriano2, James Di Santo2, Françoise Dromer2, Gérard Eberl2, Jost Enninga2, Jacques Fellay4, Ivo Gomperts-Boneca2, Milena Hasan2, Serge Hercberg5, Olivier Lantz6, Hugo Mouquet2, Etienne Patin2, Sandra Pellegrini2, Stanislas Pol7, Antonio Rausell8, Lars Rogge2, Anavaj Sakuntabhai2, Olivier Schwartz2, Benno Schwikowski2, Spencer Shorte2, Frédéric Tangy2, Antoine Toubert9, Mathilde Touvier10, Marie-Noëlle Ungeheuer2, Matthew L. Albert11*, Darragh Duffy2*, Lluis Quintana-Murci2* 1INSERM U1163, University of Paris, Imagine Institute, Paris, France. 2Pasteur Institute, Paris, France. 3Lund University, Lund, Sweden. 4EPFL, Lausanne, Switzerland. 5Université Paris 13, Paris, France. 6Curie Institute, Paris, France. 7Cochin Hospital, Paris, France. 8INSERM UMR 1163 – Institut Imagine. 9Hôpital Saint-Louis, Paris, France. 10Université Paris 13, Paris, France. 11In Sitro. *Co-coordinators of the Milieu Intérieur Consortium. Additional information can be found at: https://www.pasteur.fr/labex/milieu-interieur., CoV-Contact Cohort Loubna Alavoine1, Karine K. A. Amat2, Sylvie Behillil3, Julia Bielicki4, Patricia Bruijning5, Charles Burdet6, Eric Caumes7, Charlotte Charpentier8, Bruno Coignard9, Yolande Costa1, Sandrine Couffin-Cardièrgues10, Florence Damond8, Aline Dechanet11, Christelle Delmas10, Diane Descamps8, Xavier Duval1, Jean-Luc Ecobichon1, Vincent Enouf3, Hélène Espérou10, Wahiba Frezouls1, Nadhira Houhou11, Emila Ilic-Habensus1, Ouifiya Kafif11, John Kikoine11, Quentin Le Hingrat8, David Lebeaux12, Anne Leclercq1, Jonathan Lehacaut1, Sophie Letrou1, Bruno Lina13, Jean-Christophe Lucet14, Denis Malvy15, Pauline Manchon11, Milica Mandic1, Mohamed Meghadecha16, Justina Motiejunaite17, Mariama Nouroudine1, Valentine Piquard11, Andreea Postolache11, Caroline Quintin1, Jade Rexach1, Layidé Roufai10, Zaven Terzian11, Michael Thy18, Sarah Tubiana1, Sylvie van der Werf3, Valérie Vignali1, Benoit Visseaux8, Yazdan Yazdanpanah14 1Centre d'Investigation Clinique, Inserm CIC 1425, Hôpital Bichat Claude Bernard, APHP, Paris, France. 2IMEA Fondation Léon M'Ba, Paris, France. 3Institut Pasteur, UMR 3569 CNRS, Université de Paris, Paris, France. 4University of Basel Children’s Hospital. 5Julius Center for Health Sciences and Primary Care, Utrecht. 6Université de Paris, IAME, Inserm UMR 1137, F-75018, Paris, France, Hôpital Bichat Claude Bernard, APHP, Paris, France. 7Hôpital Pitiè Salpétriere, APHP, Paris. 8Université de Paris, IAME, INSERM UMR 1137, AP-HP, University hospital Bichat Claude Bernard, Virology, F-75018 Paris, France. 9Santé Publique France, Saint Maurice, France. 10Pole Recherche Clinique, Inserm, Paris France. 11Hôpital Bichat Claude Bernard, APHP, Paris, France. 12APHP, Paris, France. 13Virpath Laboratory, International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France . 14IAME Inserm UMR 1138, Hôpital Bichat Claude Bernard, APHP, Paris, France. 15Service des Maladies Infectieuses et Tropicales; Groupe Pellegrin-Place Amélie-Raba-Léon, BORDEAUX. 16Hôpital Hotel Dieu, APHP, Paris, France. 17ervice des explorations fonctionnelles, Hôpital Bichat- Claude Bernard, APHP, Paris, France. 18Center for Clinical Investigation, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital., Amsterdam UMC Covid-19 Biobank Michiel van Agtmael1, Anne Geke Algera2, Frank van Baarle2, Diane Bax3, Martijn Beudel4, Harm Jan Bogaard5, Marije Bomers1, Lieuwe Bos2, Michela Botta2, Justin de Brabander6, Godelieve Bree6, Matthijs C. Brouwer4, Sanne de Bruin2, Marianna Bugiani7, Esther Bulle2, O. Chouchane1, Alex Cloherty3, Paul Elbers2, Lucas Fleuren2, Suzanne Geerlings1, Bart Geerts8, Theo Geijtenbeek9, Armand Girbes2, Bram Goorhuis1, Martin P. Grobusch1, Florianne Hafkamp9, Laura Hagens2, Jorg Hamann10, Vanessa Harris1, Robert Hemke11, Sabine M. Hermans1, Leo Heunks2, Markus Hollmann8, Janneke Horn2, Joppe W. Hovius1, Menno de Jong12, Rutger Koning4, Mourik van Mourik2, Jeaninne Nellen1, Frederique Paulus2, Edgar Peters1, Tom van der Poll1, Bennedikt Preckel8, Jan M. Prins1, Jorinde Raasveld2, Tom Reijnders1, Michiel Schinkel1, Marcus Schultz2, Alex Schuurman13, Kim Sigaloff1, Marry Smit2, Cornelis S. Stijnis1, Willemke Stilma2, Charlotte Teunissen14, Patrick Thoral2, Anissa Tsonas2, Marc van der Valk1, Denise Veelo8, Alexander P. J. Vlaar15, Heder de Vries2, Michèle van Vugt1, W. Joost Wiersinga1, Dorien Wouters16, A. H. (Koos) Zwinderman17, Diederik van de Beek18* 1Department of Infectious Diseases, Amsterdam UMC, Netherlands. 2Department of Intensive Care, Amsterdam UMC, Netherlands. 3Experimental Immunology, Amsterdam UMC, Netherlands. 4Department of Neurology, Amsterdam UMC, Netherlands. 5Department of Pulmonology, Amsterdam UMC, Netherlands. 6Department of Infectious Diseases, Amsterdam UMC, Netherlands. 7Department of Pathology, Amsterdam UMC, Netherlands. 8Department of Anesthesiology, Amsterdam UMC, Netherlands. 9Department of Experimental Immunology, Amsterdam UMC, Netherlands. 10Amsterdam UMC, THE NETHERLANDS Biobank Core Facility, Amsterdam UMC, Netherlands. 11Department of Radiology, Amsterdam UMC, Netherlands. 12Department of Medical Microbiology, Amsterdam UMC, Netherlands. 13Department of Internal Medicine, Amsterdam UMC, Netherlands. 14Neurochemical Laboratory, Amsterdam UMC, Netherlands. 15Deparment of Intensive Care, Amsterdam UMC, Netherlands. 16Department of Clinical Chemistry, Amsterdam UMC, Netherlands. 17Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, Netherlands. 18Department of Neurology, Amsterdam UMC, Netherlands. *Leader of the AMC consortium., COVID Human Genetic Effort Laurent Abel1, Alessandro Aiuti2, Saleh Al Muhsen3, Fahd Al-Mulla4, Mark S. Anderson5, Andrés Augusto Arias6, Hagit Baris Feldman7, Dusan Bogunovic8, Alexandre Bolze9, Anastasiia Bondarenko10, Ahmed A. Bousfiha11, Petter Brodin12, Yenan Bryceson12, Carlos D. Bustamante13, Manish Butte14, Giorgio Casari15, Samya Chakravorty16, John Christodoulou17, Elizabeth Cirulli9, Antonio Condino Neto18, Megan A. Cooper19, Clifton L. Dalgard20, Joseph L. DeRisi21, Murkesh Desai22, Beth A. Drolet23, Sara Espinosa24, Jacques Fellay25, Carlos Flores26, Jose Luis Franco27, Peter K. Gregersen28, Filomeen Haerynck29, David Hagin30, Rabih Halwani​31, Jim Heath32, Sarah E. Henrickson33, Elena Hsieh34, Kohsuke Imai35, Yuval Itan8, Timokratis Karamitros36, Kai Kisand37, Cheng-Lung Ku38, Yu-Lung Lau39, Yun Ling40, Carrie L. Lucas41, Tom Maniatis42, Davoud Mansouri43, Laszlo Marodi44, Isabelle Meyts45, Joshua Milner46, Kristina Mironska47, Trine Mogensen48, Tomohiro Morio49, Lisa P. Ng50, Luigi D. Notarangelo51, Giuseppe Novelli52, Antonio Novelli53, Cliona O'Farrelly54, Satoshi Okada55, Tayfun Ozcelik56, Rebeca Perez de Diego57, Anna M. Planas58, Carolina Prando59, Aurora Pujol60, Lluis Quintana-Murci61, Laurent Renia62, Alessandra Renieri63, Carlos Rodríguez-Gallego64, Vanessa Sancho-Shimizu65, Vijay Sankaran66, Kelly Schiabor Barrett9, Mohammed Shahrooei67, Andrew Snow68, Pere Soler-Palacín69, András N. Spaan70, Stuart Tangye71, Stuart Turvey72, Furkan Uddin73, Mohammed J. Uddin74, Diederik van de Beek75, Sara E. Vazquez76, Donald C. Vinh77, Horst von Bernuth78, Nicole Washington9, Pawel Zawadzki79, Helen C. Su51*, Jean-Laurent Casanova80* 1INSERM U1163, University of Paris, Imagine Institute, Paris, France. 2San Raffaele Telethon Institute for Gene Therapy, IRCCS Ospedale San Raffaele, Milan, Italy. 3King Saud University, Riyadh, Saudi Arabia. 4Kuwait University, Kuwait City, Kuwait. 5University of California, San Francisco, San Francisco, CA, USA. 6Universidad de Antioquia, Group of Primary Immunodeficiencies, Antioquia, Colombia. 7The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 8Icahn School of Medicine at Mount Sinai, New York, NY, USA. 9Helix, San Mateo, CA, USA. 10Shupyk National Medical Academy for Postgraduate Education, Kiev, Ukraine. 11Clinical immunology unit, pediatric infectious disease departement, Faculty of Medicine and Pharmacy, Averroes University Hospital. LICIA Laboratoire d'immunologie clinique, d'inflammation et d'allergie, Hassann Ii University., Casablanca, Morocco. 12Karolinska Institute, Stockholm, Sweden. 13Stanford University, Stanford, CA, USA. 14University of California, Los Angeles, CA, USA. 15Medical Genetics, IRCCS Ospedale San Raffaele, Milan, Italy. 16Emory, Atlanta, GA, USA. 17Murdoch Children's Research Institute, Victoria, Australia. 18University of São Paulo, São Paulo, Brazil. 19Washington University School of Medicine, St. Louis, MO, USA. 20The American Genome Center; Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 21University of California San Francisco; Chan Zuckerberg Biohub, San Francisco, CA, United States. 22Bai Jerbai Wadia Hospital for Children, Mumbai, India. 23 School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. 24Instituto Nacional de Pediatria (National Institute of Pediatrics), Mexico City, Mexico. 25Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland. 26Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Canarian Health System, Santa Cruz de Tenerife, Spain. 27University of Antioquia, Medellín, Colombia. 28Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY, USA. 29Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPIG), PID research lab, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Edegem, Belgium. 30The Genetics Institute Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 31Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, UAE. 32Institute for Systems Biology, Seattle, WA, USA. 33Children's Hospital of Philadelphia, Philadelphia, PA, USA. 34Anschutz Medical Campus, Aurora, CO, USA. 35Riken, Tokyo, Japan. 36Hellenic Pasteur Institute, Athens, Greece. 37University of Tartu, Tartu, Estonia. 38Chang Gung University, Taoyuan County, Taiwan. 39The University of Hong Kong, Hong Kong, China. 40Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. 41Yale School of Medicine, New Haven, CT, USA. 42New York Genome Center, New York, NY, USA. 43Shahid Beheshti University of Medical Sciences, Tehran, Iran. 44Semmelweis University Budapest, Budapest, Hungary. 45KU Leuven, Department of Immunology, Microbiology and Transplantation, Leuven, Belgium. 46Columbia University Medical Center, New York, NY, USA. 47University Clinic for Children's Diseases, Skopje, North Macedonia. 48Aarhus University, Aarhus, Denmark. 49Tokyo Medical & Dental University Hospital, Tokyo, Japan. 50Singapore Immunology Network, Singapore. 51National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 52Bambino Gesù Children's Hospital, Rome, Italy; Dept. Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy. 53Bambino Gesù Children's Hospital, Rome, Italy, Rome, Italy, Italy. 54Trinity College, Dublin, Ireland. 55Hiroshima University, Hiroshima, Japan. 56Bilkent University, Ankara, Turkey. 57Laboratory of Immunogenetics of Human Diseases, Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz Hospital, Madrid 28046, Spain, EU, Madrid, Spain, Spain. 58IIBB-CSIC, IDIBAPS, Barcelona, Spain. 59Faculdades Pequeno Príncipe e Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil. 60Neurometabolic Diseases Laboratory, IDIBELL- Hospital Duran I Reynals; Catalan Institution for Research and Advanced Studies (ICREA); CIBERER U759, ISCiii Madrid Spain, Barcelona, Spain. 61Institut Pasteur (CNRS UMR2000) and Collège de France, Paris, France. 62Infectious Diseases Horizontal Technology Center and Singapore Immunology Network, Agency for Science Technology (A*STAR), Singapore. 63University of Siena, Siena, Italy. 64Hospital Universitario de Gran Canaria Dr Negrín, Canarian Health System, Canary Islands, Spain. 65Imperial College London, London, UK. 66Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 67Saeed Pathobiology and Genetic Lab, Tehran, Iran. 68Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, USA. 69Hospital Universitari Vall d'Hebron, Barcelona, Spain. 70University Medical Center Utrecht, Amsterdam, Netherlands. 71Garvan Institute of Medical Research, Sydney, Australia. 72The University of British Columbia, Vancouver, Canada. 73Holy Family Red Crescent Medical College; Centre for Precision Therapeutics, NeuroGen Children's Healthcare; Genetics and Genomic Medicine Centre, NeuroGen Children's Healthcare, Dhaka, Bangladesh. 74Mohammed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, UAE; The Centre for Applied Genomics, Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada, Dhaka, Bangladesh. 75Amsterdam UMC, Amsterdam, Netherlands. 76University of California, San Francisco, San Francisco, CA, United States. 77McGill University Health Centre, Montreal, Canada. 78Charité - Berlin University Hospital Center, Berlin, Germany. 79Molecular Biophysics Division, Faculty of Physics, A. Mickiewicz University, Uniwersytetu Poznanskiego 2, Poznań, Poland. 80Rockefeller University, Howard Hughes Medical Institute, Necker Hospital, New York, NY, USA. *Leaders of the COVID Human Genetic Effort., Interindividual clinical variability in the course of SARS-CoV-2 infection is immense. We report that at least 101 of 987 patients with life-threatening COVID-19 pneumonia had neutralizing IgG auto-Abs against IFN-ω (13 patients), the 13 types of IFN-α (36), or both (52), at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1,227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 were men. A B cell auto-immune phenocopy of inborn errors of type I IFN immunity underlies life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62- IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project, ANRS-COV05, the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, Institut Institut National de la Santé et de la Recherche Médicale (INSERM) and the University of Paris. Samples from San Raffaele Hospital were obtained within the Covid-BioB project and healthcare personnel of San Raffaele Hospital, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) clinical lab and clinical research Unit; funded by the Program Project COVID-19 OSR-UniSR and Fondazione Telethon. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). The “Milieu Intérieur” cohort was supported by was supported by the French Government’s Investissement d’Avenir Program, Laboratoire d’Excellence “Milieu Intérieur” Grant (ANR-10-LABX-69-01) (PI: L QuintanaMurci & D Duffy). The Simoa experiment was supported by the PHRC-20-0375 COVID-19 grant “DIGITAL COVID” (PI: G Gorochov). SGT is supported by a Leadership 3 Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a COVID19 Rapid Response Grant awarded by UNSW Sydney. CRG and colleagues were supported by Instituto de Salud Carlos III (COV20_01333 and COV20_01334, Spanish Ministry of Science and Innovation -RTC-2017-6471-1; AEI/FEDER, UE), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). SA and AB were supported by ANR-20-COVI-0064 (PI: A Belot). This work is supported by the French Ministry of Health “Programme Hospitalier de Recherche Clinique Inter regional 2013”, by the Contrat de Plan Etat-Lorraine and FEDER Lorraine, and a public grant overseen by the French National Research Agency (ANR) as part of the second “Investissements d’Avenir” program FIGHT-HF (reference: ANR-15-RHU-0004) and by the French PIA project “Lorraine Université d’Excellence”, reference ANR15-IDEX-04-LUE (45) and biobanking is performed by the Biological Resource Center Lorrain BB-0033-00035. This study was supported by the Fonds IMMUNOV, for Innovation in Immunopathology and by a grant from the Agence National de la Recherche (ANR-flash Covid19 “AIROCovid” to FRL), and by the FAST Foundation (French Friends of Sheba Tel Hashomer Hospital). Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1, a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The Amsterdam UMC Covid-19 Biobank was supported by grants of the Amsterdam Corona Research Fund, Dr. C.J. Vaillant Fund, and Netherlands Organization for Health Research and Development (ZonMw; NWO-Vici-Grant [grant number 918·19·627 to DvdB]. This work was also supported by the Division of Intramural Research of the National Institute of Dental Craniofacial Research and National Institute of Allergy and Infectious Diseases, National Institutes of Health, and by Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e comorbidita”). The opinions and assertions expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Uniformed Services University or the Department of Defense. JH holds an Institut Imagine MD-PhD fellowship from the Fondation Bettencourt Schueller. JR is supported by the Inserm PhD program (“poste d’accueil Inserm”). PB was supported by the French Foundation for Medical Research (FRM, EA20170638020) and the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). We thank the Association “Turner et vous” for their help and support. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. DCV is supported by the Fonds de la recherche en santé du Québec clinician-scientist scholar program. K. Kisand was supported by the Estonian Research Council grant PUT1367. We thank the GEN-COVID Multicenter Study (https://sites.google.com/dbm.unisi.it/gen-covid). We thank the NIAID Office of Cyber Infrastructure and Computational Biology, Bioinformatics and Computational Biosciences Branch (Contract HHSN316201300006W/HHSN27200002 to MSC, Inc) and Operations Engineering Branch for developing the HGRepo system to enable streamlined access to the data and the NCI Advanced Biomedical Computational Science (ABCS) for data transformation support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

  • Bastard, Paul
  • Gervais, Adrian
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Manry, Jérémy
  • Michailidis, Eleftherios
  • Hoffmann, Hans-Heinrich
  • Eto, Shohei
  • García-Prat, Marina
  • Bizien, Lucy
  • Martínez-Picado, Javier
  • Raoult, Didier
  • Vasse, Marc
  • Gregersen, Peter K.
  • Piemonti, Lorenzo
  • Rodríguez-Gallego, Carlos
  • Notarangelo, Luigi D.
  • Su, Helen C.
  • Kisand, Kai
  • Luyt, Charles-Edouard
  • Kan, Nelli
  • Okada, Satoshi
  • Puel, Anne
  • Jouanguy, Emmanuelle
  • Rice, Charles M.
  • Tiberghien, Pierre
  • Zhang, Qian
  • Cobat, Aurélie
  • Abel, Laurent
  • Casanova, Jean-Laurent
  • Amador-Borrero, Blanca
  • Shcherbina, Anna
  • Gaudet, Alexandre
  • Poissy, Julien
  • Morel, Pascal
  • Richard, Pascale
  • Cognasse, Fabrice
  • Troya, Jesús
  • Trouillet-Assant, Sophie
  • Belot, Alexandre
  • Saker, Kahina
  • Garçon, Pierre
  • Lau, Yu-Lung
  • Rivière, Jacques G.
  • Lagier, Jean-Christophe
  • Gentile, Stephanie
  • Rosen, Lindsey B.
  • Shaw, Elana
  • Morio, Tomohiro
  • Tanaka, Junko
  • Dalmau, David
  • Tharaux, Pierre-Louis
  • Sene, Damien
  • Leung, Daniel
  • Stépanian, Alain
  • Mégarbane, Bruno
  • Triantafyllia, Vasiliki
  • Fekkar, Arnaud
  • Heath, James R.
  • Franco, José Luis
  • Anaya, Juan Manuel
  • Solé-Violán, Jordi
  • Imberti, Luisa
  • Biondi, Andrea
  • Coulongeat, Matthieu
  • Bonfanti, Paolo
  • Castagnoli, Riccardo
  • Delmonte, Ottavia M.
  • Zhang, Yu
  • Snow, Andrew L.
  • Holland, Steven M.
  • Biggs, Catherine M.
  • Moncada-Velez, Marcela
  • Arias, Andrés Augusto
  • Lorenzo, Lazaro
  • Marlet, Julien
  • Boucherit, Soraya
  • Coulibaly, Boubacar
  • Anglicheau, Dany
  • Planas, Anna M.
  • Haerynck, Filomeen
  • Duvlis, Sotirija
  • Nussbaum, Robert
  • Ozcelik, Tayfun
  • Keles, Sevgi
  • Bousfiha, Ahmed Aziz
  • Koning, Rutger
  • El Bakkouri, Jalila
  • Ramírez-Santana, Carolina
  • Paul, Stephanie
  • Pan-Hammarström, Qiang
  • Hammarström, Lennart
  • Dupont, Annabelle
  • Kurolap, Alina
  • Metz, Christine N.
  • Aiuti, Alessandro
  • Casari, Giorgio
  • Reyes, Luis Felipe
  • Lampasona, Vito
  • Ciceri, Fabio
  • Barreiros, Lucila
  • Domínguez-Garrido, Elena
  • Vidigal, Mateus
  • Zatz, Mayana
  • Beek, Diederik van der
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Stepanovskyy, Yuriy
  • Chauvineau-Grenier, Angélique
  • Boyarchuk, Oksana
  • Nukui, Yoko
  • Tsumura, Miyuki
  • Vidaur, Loreto
  • Tangye, Stuart G.
  • Burrel, Sonia
  • Duffy, Darragh
  • Quintana-Murci, Lluis
  • Klocperk, Adam
  • Venet, Fabienne
  • Parra-Martínez, Alba
  • Monneret, Guillaume
  • Nussenzweig, Michel C.
  • Arrestier, Romain
  • Boudhabhay, Idris
  • Baris, Hagit N.
  • Hagin, David
  • Wauters, Joost
  • Meyts, Isabelle
  • Dyer, Adam
  • Kennelly, Sean p.
  • Yang, Rui
  • Bourke, Nollaig
  • Halwani, Rabih
  • Sharif-Askari, Narjes Saheb
  • Dorgham, Karim
  • Sallette, Jerome
  • Mehlal-Sedkaoui, Souad
  • Alkhater, Suzan
  • Rigo-Bonnin, Raúl
  • Morandeira, Francisco
  • Roussel, Lucie
  • Haljasmägi, Liis
  • Vinh, Donald C.
  • Ostrowski, Sisse Rye
  • Condino-Neto, Antonio
  • Prando, Carolina
  • Bondarenko, Anastasiia
  • Spaan, András N.
  • Gilardin, Laurent
  • Fellay, Jacques
  • Lyonnet, Stanislas
  • Bilguvar, Kaya
  • Migaud, Mélanie
  • Lifton, Richard P.
  • Mane, Shrikant M.
  • HGID Lab
  • COVID Clinicians
  • COVID-STORM Clinicians
  • NIAID Immune Response to COVID Group
  • NH-COVAIR Study Group
  • Danish CHGE
  • Danish Blood Donor Study
  • St. James's Hospital SARS CoV2 Interest Group
  • Särekannu, Karita
  • French COVID Cohort Study Group
  • Imagine COVID Group
  • The Milieu Intérieur Consortium
  • CoV-Contact Cohort
  • Amsterdam UMC Covid-19 Biobank
  • COVID Human Genetic Effort
  • Constances Cohort
  • Dijon Study
  • Cerba HealthCare
  • Etablissement du Sang Study Group
  • Maslovskaja, Julia
  • Anderson, MarK S.
  • Boisson, Bertrand
  • Béziat, Vivien
  • Zhang, Shen-Ying
  • Andreakos, Evangelos
  • Hermine, Olivier
  • Pujol, Aurora
  • Peterson, Pärt
  • Mogensen, Trine
  • Rowen, Lee
  • Prost, Nicolas de
  • Mond, James
  • Debette, Stephanie
  • Lamballerie, Xavier de
  • Duval, Xavier
  • Mentré, France
  • Zins, Marie
  • Soler-Palacín, Pere
  • Colobran, Roger
  • Gorochov, Guy
  • Solanich, Xavier
  • Tandjaoui-Lambiotte, Yacine
  • Susen, Sophie
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 (coronavirus disease 2019) pneumonia but not in individuals with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or IFN-ω (100 pg/ml; in 1:10 dilutions of plasma) in 13.6% of 3595 patients with critical COVID-19, including 21% of 374 patients >80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1124 deceased patients (aged 20 days to 99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected individuals from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or IFN-ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of individuals carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over 80s and total fatal COVID-19 cases., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Awards (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS Nord-Sud (ANRS-COV05), ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 824110 (EASI-Genomics), the Square Foundation, Grandir–Fonds de solidarité pour l’Enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM; and the University of Paris. P.B. was supported by the FRM (EA20170638020). P.B., J.R., and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt Schueller). Work in the Laboratory of Virology and Infectious Disease was supported by the NIH (P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1), a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). This work was also partly supported by the Intramural Research Program of the NIAID and NIDCR, NIH (grants ZIA AI001270 to L.D.N. and 1ZIAAI001265 to H.C.S.). This program is supported by the Agence Nationale de la Recherche (reference ANR-10-LABX-69-01). K.K.’s group was supported by the Estonian Research Council grants PRG117 and PRG377. R.H. was supported by an Al Jalila Foundation Seed Grant (AJF202019), Dubai, UAE, and a COVID-19 research grant (CoV19-0307) from the University of Sharjah, UAE. S.G.T. is supported by Investigator and Program Grants awarded by the National Health and Medical Research Council of Australia and a UNSW Sydney COVID Rapid Response Initiative Grant. L.I. reported funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). L.I. and G. L. Marseglia reported funding from Regione Lombardia, Italy (project Risposta immune in pazienti con COVID-19 e co-morbidità). This research was partially supported by the Instituto de Salud Carlos III (COV20/0968). J.R.H. reported funding from Biomedical Advanced Research and Development Authority HHSO10201600031C. S.O. reports funding Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development, AMED (grant number JP20fk0108531). G.G. was supported by ANR Flash COVID-19 program and SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University iCOVID programs. The Three-City (3C) Study was conducted under a partnership agreement among the INSERM, the Victor Segalen Bordeaux 2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also supported by the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Direction générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme “Cohortes et collections de données biologiques”. S. Debette was supported by the University of Bordeaux Initiative of Excellence. P.K.G. reports funding from the National Cancer Institute, NIH, under contract no. 75N91019D00024, task order no. 75N91021F00001. J.W. is supported by an FWO Fundamental Clinical Mandate (1833317N). Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. Work at Vall d’Hebron was also partly supported by research funding from Instituto de Salud Carlos III grant PI17/00660 cofinanced by the European Regional Development Fund (ERDF). C.R.-G. and colleagues of the Canarian Health System Sequencing Hub were supported by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334, Spanish Ministry for Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE), Fundación DISA (OA18/017 and OA20/024), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). C.M.B. is supported by a MSFHR Health Professional-Investigator Award. P.Q.H. and L.H. were funded by the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650). Work at Y.-L.L.’s laboratory in the University of Hong Kong (HKU) was supported by the Society for the Relief of Disabled Children. MBBS/PhD study of D.L. in HKU was supported by the Croucher Foundation. J.L.F. was supported in part by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX (806-2018) and Colciencias contract 713-2016 (code 111574455633)]. A.K. was in part supported by grants NU20-05-00282 and NV18-05-00162 issued by the Czech Health Research Council and Ministry of Health, Czech Republic. L.P. was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617). I.M. is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies; by the KU Leuven C1 grant C16/18/007; by a VIB-GC PID grant; by the FWO frants G0C8517N, G0B5120N, and G0E8420N; and by the Jeffrey Modell Foundation. I.M. has received funding under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948959). E.A. received funding from the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). M.Vi received funding from the São Paulo Research Foundation (FAPESP) (grant number 2020/09702-1) and JBS SA (grant number 69004). The NH-COVAIR study group consortium was supported by a grant from the Meath Foundation, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

  • Zhang, Qian
  • Pizzorno, Andrés
  • Miorin, Lisa
  • Bastard, Paul
  • Gervais, Adrian
  • Le Voyer, Tom
  • Bizien, Lucy
  • Manry, Jeremy
  • Rosain, Jérémie
  • Philippot, Quentin
  • Goavec, Kelian
  • Padey, Blandine
  • Cupic, Anastasija
  • Laurent, Emilie
  • Saker, Kahina
  • Vanker, Martti
  • Särekannu, Karita
  • García-Salum, Tamara
  • Ferres, Marcela
  • Le Corre, Nicole
  • Sánchez-Céspedes, Javier
  • Balsera-Manzanero, María
  • Carratalà, Jordi
  • Retamar Gentil, Pilar
  • Abelenda, Gabriela
  • Valiente-Méndez, Adoración
  • Tiberghien, Pierre
  • Zins, Marie
  • Debette, Stéphanie
  • Meyts, Isabelle
  • Haerynck, Filomeen
  • Castagnoli, Riccardo
  • Notarangelo, Luigi D.
  • González-Granado, Luis
  • Domínguez-Pinilla, Nerea
  • Andreakos, Evangelos
  • Triantafyllia, Vasiliki
  • Rodríguez-Gallego, Carlos
  • Solé-Violán, Jordi
  • Ruiz-Hernández, José Juan
  • Rodríguez de Castro, Felipe
  • Ferreres-Franco, José
  • Briones, Marisa
  • Wauters, Joost
  • Vanderbeke, Lore
  • Feys, Simon
  • Kuo, Chen-Yen
  • Lei, Wei-Te
  • Ku, Cheng-Lung
  • Tal, Galit
  • Etzioni, Amos
  • Hanna, Suhair
  • Fournet, Thomas
  • Casalegno, Jean-Sebastien
  • Queromes, Gregory
  • Argaud, Laurent
  • Javouhey, Etienne
  • Rosa-Calatrava, Manuel
  • Cordero, Elisa
  • Aydillo, T. A.
  • Medina López, Rafael Antonio
  • Kisand, Kai
  • Puel, Anne
  • Jouanguy, Emmanuelle
  • Abel, Laurent
  • Cobat, Aurélie
  • Trouillet-Assant, Sophie
  • García-Sastre, Adolfo
  • Casanova, Jean-Laurent
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10-5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10-10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH; R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences, NIH Clinical and Translational Science Award program (UL1 TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (EQU201903007798), the ANRS-COV05, ANR-RHU program ANR-21-RHUS-08, ANR GENVIR (ANR-20-CE93-003), ANR GenMISC (ANR-21-COVR-0039), and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir–Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, and the Université Paris Cité. This work was partly supported by the Center for Research on Influenza Pathogenesis and Transmission, a National Institute of Allergy and Infectious Diseases (NIAID)–funded Center of Excellence for Influenza Research and Response (contract no. 75N93021C00014), and the FLUOMICS Consortium (NIH-NIAID grant U19AI135972) to both A. García-Sastre and R.A. Medina, and by NIAID grant U19AI142733 and U19AI168631 to A. García-Sastre. Work in the Medina laboratory was also supported by the PIA ACT 1408, FONDECYT 1161971 and 1212023 grants from Agencia Nacional de Investigación y Desarrollo of Chile. The VirPath team is supported by INSERM REACTing (Research & Action Emerging Infectious Diseases), CNRS, and Mérieux Research grants. B. Padey is supported by an ANRT CIFRE PhD scholarship. For the Lyon cohort, specimen collection and study was supported by a grant from the French Ministry of Health PHRC-I 2013 ANTIGRIPPE. C. Rodríguez-Gallego and colleagues were supported by the Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI12/01565, Spanish Ministry for Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE), Grupo DISA, Fundación MAPFRE Guanarteme, Sociedad Española de Neumología y Cirugía Torácica and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas, científicas del Instituto Tecnológico y de Energías Renovables para colaborar en la lucha contra la COVID-19”). E. Andreakos is supported by the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). P. Bastard was supported by the French Foundation for Medical Research (EA20170638020) and by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). This study was supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009); cofinanced by European Regional Development Fund “A way to achieve Europe”; Operative Program Intelligence Growth 2014-2020 (CB21/13/00006) also was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–Next Generation EU and Consejería de Economía, Conocimiento, Empresas y Universidad, Secretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía, Spain (P18-RT-3320). I. Meyts is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies, a CSL-Behring Research Grant, KU Leuven C1 grant C16/18/007, a VIB GC PID Grant, Fonds Wetenschappelijk Onderzoek grants G0C8517N, G0B5120N, and G0E8420N, and the Jeffrey Modell Foundation. Open Access funding provided by Rockefeller University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel genes and sex differences in COVID-19 severity

  • Cruz Modino, Raquel de la
  • Diz-de Almeida, Silvia
  • López de Heredia, Miguel
  • Quintela, Inés
  • Ceballos, Francisco C.
  • Pita, Guillermo
  • Lorenzo-Salazar, José M.
  • González-Montelongo, Rafaela
  • Gago-Dominguez, Manuela
  • Sevilla Porras, Marta
  • Tenorio Castaño, Jair Antonio
  • Carbonell, Cristina
  • Migeotte, Isabelle
  • Renieri, Alessandra
  • Aguilera-Albesa, Sergio
  • Planas, Anna M.
  • Ludwig, Kerstin U.
  • Buti, María
  • Rahmouni, Souad
  • Alarcón-Riquelme, M. E.
  • Schulte, Eva C.
  • Tamayo-Velasco, Álvaro
  • Franke, Andre
  • Castaño, Luis
  • Karlsen, Tom H.
  • Valenti, Luca
  • Zeberg, Hugo
  • Almadana Pacheco, Virginia
  • Richards, Brent
  • Ganna, Andrea
  • Boada, Mercè
  • Rojas, Itziar de
  • Gil-Fournier, Belén
  • Ruiz, Agustín
  • Sánchez-Juan, Pascual
  • Castelao, Jose E.
  • Real, Luis Miguel
  • SCOURGE Cohort Group
  • HOSTAGE Cohort Group
  • GRA@CE Cohort Group
  • Almoguera, Berta
  • Guillen-Navarro, Encarna
  • Ayuso, Carmen
  • Gómez-Arrue, Javier
  • González-Neira, Anna
  • Riancho, José A.
  • Rojas-Martinez, Augusto
  • Conde-Vicente, Rosa
  • Flores, Carlos
  • Lapunzina, Pablo
  • Carracedo, Ángel
  • Álvarez, Nuria
  • Andreu-Bernabeu, Álvaro
  • Arana-Arri, Eunate
  • González Álvarez, Beatriz
  • Arango, Celso
  • Arranz, Maria J.
  • Artiga, María Jesús
  • Baptista-Rosas, Raúl C.
  • Cordero-Lorenzana, M. Lourdes
  • Barreda-Sánchez, María
  • Belhassen-García, Moncef
  • Bezerra, Joao F.
  • Bezerra, Marcos A. C.
  • Boix-Palop, Lucía
  • Gonzalez Bernaldo de Quirós, Fernán
  • Briones, María
  • Brugada, Ramón
  • Bustos, Matilde
  • Cortés-Sánchez, José L.
  • Cortón, Marta
  • Darnaude, M. Teresa
  • De Martino-Rodríguez, Alba
  • Tamayo, Eduardo
  • Campo-Pérez, Víctor de
  • Diaz de Bustamante, Aranzazu
  • González-Peñas, Javier
  • Domínguez-Garrido, Elena
  • Luchessi, Andre D.
  • Eiros, Rocío
  • Estigarribia Sanabria, Gladys Mercedes
  • Fariñas, María del Carmen
  • Fernández-Robelo, Uxía
  • Fernández-Rodríguez, Amanda
  • Fernández-Villa, Tania
  • Gutiérrez-Bautista, Juan F.
  • Herrero, María José
  • Herrero-Gonzalez, Antonio
  • Jiménez-Sousa, María A.
  • Aguado, José María
  • Lattig, María Claudia
  • Taracido-Fernandez, Juan Carlos
  • Liger Borja, Anabel
  • López-Rodríguez, Rosario
  • Mancebo, Esther
  • Martín-López, Caridad
  • Martín, Vicente
  • Martínez-Nieto, Oscar
  • Martinez-López, Icíar
  • Martinez-Resendez, Michel F.
  • Amitrano, Sara
  • Martínez-Pérez, Àngel
  • Mazzeu, Juliana F
  • Teper, Alejandro
  • Merayo Macías, Eleuterio
  • Mínguez, Pablo
  • Moreno Cuerda, Víctor
  • Silbiger, Vivian N.
  • Oliveira, Silviene F.
  • Ortega-Paino, Eva
  • Parellada, Mara
  • Roade, Luisa
  • Paz-Artal, Estela
  • Santos, Ney P. C.
  • Pérez-Matute, Patricia
  • Torres-Tobar, Lilian
  • Pérez Ramírez, Patricia
  • Pérez-Tomás, M. Elena
  • Perucho, Teresa
  • Pinsach-Abuin, Mel Lina
  • Pompa-Mera, Ericka N.
  • Porras-Hurtado, Gloria L.
  • Fava, Francesca
  • Pujol, Aurora
  • Ramiro León, Soraya
  • Resino, Salvador
  • Fernandes, Marianne R.
  • Urioste, Miguel
  • Rodríguez-Ruiz, Emilio
  • Rodríguez-Artalejo, Fernando
  • Rodriguez-Garcia, José A.
  • Ruiz Cabello, Francisco
  • Ruiz-Hornillos, Javier
  • Spinner, Christoph D.
  • Ryan, Pablo
  • Soria, José Manuel
  • Souto, Juan Carlos
  • Valencia-Ramos, Juan
  • Yáñez, Zuleima
  • Zarate, Ruth
  • Nakanishi, Tomoko
  • Nevado, Julian
  • Pigazzini, Sara
  • Degenhardt, Frauke
  • Prati, Daniele
  • Butler-Laporte, Guillaume
  • Maya-Miles, Douglas
  • Bujanda, Luis
  • Bouysran, Youssef
  • Palom, Adriana
  • Ellinghaus, David
  • Martínez-Bueno, Manuel
  • Rolker, Selina
  • Bernardo, David
  • García, Federico
  • Darcis, Gilles
  • Fernández-Cadenas, Israel
  • Calderón, Enrique J.
  • Holter, Jan Cato
  • Aguilar, Carlos
  • Banales, Jesús M.
  • Frithiof, Robert
  • Duga, Stefano
  • Asselta, Rosanna
  • Costa Pereira, Alexandre de
  • Romero-Gómez, Manuel
  • Nafría-Jiménez, Beatriz
  • Hov, Johannes R.
Here, we describe the results of a genome-wide study conducted in 11 939 coronavirus disease 2019 (COVID-19) positive cases with an extensive clinical information that were recruited from 34 hospitals across Spain (SCOURGE consortium). In sex-disaggregated genome-wide association studies for COVID-19 hospitalization, genome-wide significance (P < 5 × 10-8) was crossed for variants in 3p21.31 and 21q22.11 loci only among males (P = 1.3 × 10-22 and P = 8.1 × 10-12, respectively), and for variants in 9q21.32 near TLE1 only among females (P = 4.4 × 10-8). In a second phase, results were combined with an independent Spanish cohort (1598 COVID-19 cases and 1068 population controls), revealing in the overall analysis two novel risk loci in 9p13.3 and 19q13.12, with fine-mapping prioritized variants functionally associated with AQP3 (P = 2.7 × 10-8) and ARHGAP33 (P = 1.3 × 10-8), respectively. The meta-analysis of both phases with four European studies stratified by sex from the Host Genetics Initiative (HGI) confirmed the association of the 3p21.31 and 21q22.11 loci predominantly in males and replicated a recently reported variant in 11p13 (ELF5, P = 4.1 × 10-8). Six of the COVID-19 HGI discovered loci were replicated and an HGI-based genetic risk score predicted the severity strata in SCOURGE. We also found more SNP-heritability and larger heritability differences by age (<60 or ≥60 years) among males than among females. Parallel genome-wide screening of inbreeding depression in SCOURGE also showed an effect of homozygosity in COVID-19 hospitalization and severity and this effect was stronger among older males. In summary, new candidate genes for COVID-19 severity and evidence supporting genetic disparities among sexes are provided., Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B., COV20_00181 to C.A., COV20_1144 to M.A.J.S., PI20/00876 to C.F.); European Union (ERDF) ‘A way of making Europe’. Fundación Amancio Ortega, Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

  • Bastard, Paul
  • Vazquez, Sara E.
  • Liu, Jamin
  • Laurie, Matthew T.
  • Wang, Chung Yu
  • Gervais, Adrian
  • Le Voyer, Tom
  • Bizien, Lucy
  • Zamecnik, Colin
  • Philippot, Quentin
  • Rosain, Jérémie
  • Allende, Luis M.
  • Martinez-Picado, Javier
  • Ozcelik, Tayfun
  • Imberti, Luisa
  • Notarangelo, Luigi D.
  • Troya, Jesus
  • Solanich, Xavier
  • Zhang, Shen-Ying
  • Puel, Anne
  • Wilson, Michael R.
  • Trouillet-Assant, Sophie
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Ye, Chun Jimmie
  • Cobat, Aurélie
  • Thompson, Leslie M.
  • Andreakos, Evangelos
  • Zhang, Qian
  • Anderson, Mark S.
  • Casanova, Jean-Laurent
  • DeRisi, Joseph L.
  • Catherinot, Emilie
  • Willmore, Andrew
  • Mitchell, Anthea M.
  • Bair, Rebecca
  • Garçon, Pierre
  • Kenney, Heather
  • Fekkar, Arnaud
  • Salagianni, Maria
  • Poulakou, Garyphallia
  • Siouti, Eleni
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Weiss, Günter
  • Nagl, Laurenz
  • Manry, Jérémy
  • Duvlis, Sotirija
  • Arroyo-Sánchez, Daniel
  • Paz Artal, Estela
  • Rubio, Luis
  • Perani, Cristiano
  • Bezzi, Michela
  • Sottini, Alessandra
  • Quaresima, Virginia
  • Roussel, Lucie
  • Vinh, Donald C.
  • Reyes, Luis Felipe
  • Garzaro, Margaux
  • Hatipoglu, Nevin
  • Boutboul, David
  • Tandjaoui-Lambiotte, Yacine
  • Borghesi, Alessandro
  • Aliberti, Anna
  • Cassaniti, Irene
  • Venet, Fabienne
  • Monneret, Guillaume
  • Halwani, Rabih
  • Sharif-Askari, Narjes Saheb
  • Danielson, Jeffrey
  • Burrel, Sonia
  • Morbieu, Caroline
  • Stepanovskyy, Yurii
  • Bondarenko, Anastasia
  • Volokha, Alla
  • Boyarchuk, Oksana
  • Gagro, Alenka
  • Neuville, Mathilde
  • Neven, Bénédicte
  • Keles, Sevgi
  • Hernu, Romain
  • Bal, Antonin
  • Novelli, Antonio
  • Novelli, Giuseppe
  • Saker, Kahina
  • Ailioaie, Oana
  • Antolí, Arnau
  • Jeziorski, Eric
  • Rocamora-Blanch, Gemma
  • Teixeira, Carla
  • Delaunay, Clarisse
  • Lhuillier, Marine
  • Le Turnier, Paul
  • Zhang, Yu
  • Mahevas, Matthieu
  • Pan-Hammarström, Qiang
  • Abolhassani, Hassan
  • Bompoil, Thierry
  • Dorgham, Karim
  • Gorochov, Guy
  • Laouenan, Cédric
  • Rodríguez-Gallego, Carlos
  • Ng, Lisa F. P.
  • Renia, Laurent
  • Pujol, Aurora
  • Belot, Alexandre
  • Raffi, François
Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; The Rockefeller University; the St. Giles Foundation; the NIH (R01AI088364 and R01AI163029); the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866); a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University; the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the program “Investissement d’Avenir” launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) with references ANR-21-RHUS-08 and ANR-10-IAHU-01; the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM; EQU201903007798); the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), ANR AABIFNCOV (ANR-20-CO11-0001), and ANR GenMISC (ANR-21-COVR-0039) projects; the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 824110 (EASI-genomics); the Square Foundation; Grandir–Fonds de solidarité pour l’enfance; the Fondation du Souffle; the SCOR Corporate Foundation for Science; the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19); Institut National de la Santé et de la Recherche Médicale (INSERM); REACTing-INSERM; and the University of Paris. C.R.-G., R.P.D., and C.F. were funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43California grant no. 779295). L.R. and L.F.P.N. were supported by Singapore National Medical Research Council COVID-19 Research Fund (COVID19RF-001, COVID19RF-007, COVID19RF-0008, and COVID19RF-060) and A*STAR COVID-19 Research funding (H/20/04/g1/006). The UCSF COMET Consortium is supported by the Clinical and Translational Science Institute University of California, San Francisco and the NIH (U19AI077439). A.A., G.R.-B., and X.S. are funded by the 202115-31 project, funded by La Marató de TV3. L.D.N. was supported by the intramural Research Program of the NIAID, NIH. J.L.D. is supported by the Chan Zuckerberg Biohub. We acknowledge the support of the Chao Family Comprehensive Cancer Center Experimental Tissue Shared Resource, supported by the National Cancer Institute of the NIH under award number P30CA062203. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. P.B. was supported by the FRM (EA20170638020). P.B. and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul
  • Gervais, Adrian
  • Taniguchi, Maki
  • Saare, Liisa
  • Särekannu, Karita
  • Voyer, Tom Le
  • Philippot, Quentin
  • Rosain, Jérémie
  • Bizien, Lucy
  • Asano, Takaki
  • Garcia-Prat, Marina
  • Parra-Martínez, Alba
  • Migaud, Mélanie
  • Tsumura, Miyuki
  • Conti, Francesca
  • Belot, Alexandre
  • Rivière, Jacques G.
  • Morio, Tomohiro
  • Tanaka, Junko
  • Javouhey, Etienne
  • Haerynck, Filomeen
  • Duvlis, Sotirija
  • Ozcelik, Tayfun
  • Keles, Sevgi
  • Tandjaoui-Lambiotte, Yacine
  • Escoda, Simon
  • Husain, Maya
  • Pan-Hammarström, Qiang
  • Pérez-Tur, Jordi
  • Planas, Anna M.
  • Hammarström, Lennart
  • Ahlijah, Gloria
  • Haidar, Anthony Abi
  • Soudee, Camille
  • Arseguel, Vincent
  • Abolhassani, Hassan
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Nukui, Yoko
  • Hayakawa, Seiichi
  • Chrousos, George P.
  • Michos, Athanasios
  • Tatsi, Elizabeth Barbara
  • Filippatos, Filippos
  • Rodriguez-Palmero, Agusti
  • Troya, Jesus
  • Tipu, Imran
  • Meyts, Isabelle
  • Roussel, Lucie
  • Ostrowski, Sisse Rye
  • Schidlowski, Laire
  • Prando, Carolina
  • Condino-Neto, Antonio
  • Cheikh, Nathalie
  • Bousfiha, Ahmed A.
  • Bakkouri, Jalila El
  • Peterson, Pärt
  • Pujol, Aurora
  • Lévy, Romain
  • Quartier, Pierre
  • Vinh, Donald C.
  • Boisson, Bertrand
  • Béziat, Vivien
  • Zhang, Shen Ying
  • Borghesi, Alessandro
  • Pession, Andrea
  • Andreakos, Evangelos
  • Marr, Nico
  • Mentis, Alexios Fotios A.
  • Mogensen, Trine H.
  • Rodríguez-Gallego, Carlos
  • Soler-Palacin, Pere
  • Colobran, Roger
  • Tillmann, Vallo
  • Neven, Bénédicte
  • Trouillet-Assant, Sophie
  • Brodin, Petter
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Zhang, Qian
  • Martinón-Torres, Federico
  • Salas, Antonio
  • Gómez-Carballa, Alberto
  • Gonzalez-Granado, Luis I.
  • Kisand, Kai
  • Okada, Satoshi
  • Puel, Anne
  • Cobat, Aurélie
  • Casanova, Jean-Laurent
  • Aguilera-Albesa, Sergio
  • Alkhater, Suzan A.
  • Alkan, Gulsum
  • Castagnoli, Riccardo
  • Cyrus, Cyril
  • Bozdemir, Sefika Elmas
  • Emiroglu, Melike
  • Gulhan, Belgin
  • Erdeniz, Emine Hafize
  • Hatipoglu, Nevin
  • Bayhan, Gülsün Iclal
  • Jabandziev, Petr
  • Yuksek, Saliha Kanik
  • COVID Human Genetic Effort
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364, R01AI163029, and R21AI160576), the National Center for Advancing Translational Sciences, the NIH Clinical and Translational Science Award program (UL1TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the Stavros Niarchos Foundation Institute for Global Infectious Disease Research, the program “Investissement d’Avenir” launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRSCOV05, ANR GENVIR (ANR-20-CE93-003), ANR AI2D (ANR-22- CE15-0046), and ANR AAILC (ANR-21-LIBA-0002) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU COVIFERON Program (ANR-21-RHUS-08), the Square Foundation, Grandir - Fonds de solidarite pour l ´ ’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Sante et de la Recherche M ´ edicale (IN- ´ SERM), REACTing-INSERM, the University of Paris Cite and ´ Imagine Institute, Battersea & Bowery Advisory Group, and William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of Business in EMEA, and the General Atlantic Foundation. I. Meyts is a senior clinical researcher at FWO Vlaanderen; I. Meyts is funded by the European Research Council under HORIZON-HLTL-2021-ID: 101057100 "Undine," KU Leuven C16/18/007, and FWO grant G0B5120N (DADA2). L.D. Notarangelo and H.C. Su (members of the COVID Human Genetic Effort) were supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. P. Bastard was supported by the French Foundation for Medical Research (FRM, EA20170638020). P. Bastard and T. Le Voyer were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). P. Bastard was supported by the “Poste CCA-INSERM-Bettencourt” (with the support of the Fondation Bettencourt-Schueller). S. Okada was supported by MEXT/JSPS KAKENHI (grant numbers 22H03041 and 22KK0113) and AMED (grant numbers JP21fk0108436 and JP22fk0108514). L.I. Gonzalez-Granado is supported by the Instituto de Salud Carlos III (ISCIII) through the project FIS-PI21/01642 and cofunded by the European Union. D.C. Vinh is supported by a Fonds de Recherche du Quebec - Sant ´ e, Senior Clinician-Scientist scholar award. ´ Q. Pan-Hammarstrom was funded by the Swedish Research ¨ Council, and the Knut and Alice Wallenberg Foundation. K. Kisand’s laboratory was funded by the Estonian Research Council grants PRG1117 and PRG1428. This study also received support from ISCIII (TRINEO: PI22/00162; DIAVIR: DTS19/00049; ResviOmics: PI19/01039 [A. Salas]; ReSVinext: PI16/01569 [F. Martinón-Torres]; Enterogen: PI19/01090 [F. Martinón-Torres]); OMI-COVI-VAC (PI22/00406 [F. Martinón-Torres] jointly financed by FEDER), GAIN: Grupos con Potencial de Crecimiento (IN607B 2020/08 [A. Salas]); ACIS: BI-BACVIR (PRIS-3 [A. Salas]), and CovidPhy (SA 304 C [A. Salas]); and consorcio Centro de Investigación Biomedica en Red de Enfermedades Respira- ´ torias (CB21/06/00103; F. Martinón-Torres); GEN-COVID (IN845D 2020/23, F. Martinón-Torres) and Grupos de Referencia Competitiva (IIN607A2021/05, F. Martinón-Torres). The study was funded by ISCIII (COV20_01333, COV20_01334, PI16/ 00759, PI18/00223, PI19/00208, PI20/00876, and PI21/00211), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/ FEDER, EU), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43, PIFIISC22/27), Grupo DISA (OA18/017), Fundación MAPFRE Guanarteme (OA21/131), Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas cient´ıficas del ITER para colaborar en la lucha contra la COVID-19”). A. Pujol is supported by ACCI20-759 CIBERER, H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021- ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. This research is supported by the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases. Open Access funding provided by Rockefeller University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Benchmarking of human Y-chromosomal haplogroup classifiers with whole-genome and whole-exome sequence data

  • García-Olivares, Víctor
  • Muñoz-Barrera, Adrián
  • Rubio-Rodríguez, Luis A.
  • Jáspez, David
  • Díaz-de Usera, Ana
  • Iñigo-Campos, Antonio
  • Veeramah, Krishna R.
  • Alonso, Santos
  • Thomas, Mark G.
  • Lorenzo-Salazar, José M.
  • González-Montelongo, Rafaela
  • Flores, Carlos
© 2023 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., In anthropological, medical, and forensic studies, the nonrecombinant region of the human Y chromosome (NRY) enables accurate reconstruction of pedigree relationships and retrieval of ancestral information. Using high-throughput sequencing (HTS) data, we present a benchmarking analysis of command-line tools for NRY haplogroup classification. The evaluation was performed using paired Illumina data from whole-genome sequencing (WGS) and whole-exome sequencing (WES) experiments from 50 unrelated donors. Additionally, as a validation, we also used paired WGS/WES datasets of 54 individuals from the 1000 Genomes Project. Finally, we evaluated the tools on data from third-generation HTS obtained from a subset of donors and one reference sample. Our results show that WES, despite typically offering less genealogical resolution than WGS, is an effective method for determining the NRY haplogroup. Y-LineageTracker and Yleaf showed the highest accuracy for WGS data, classifying precisely 98% and 96% of the samples, respectively. Yleaf outperforms all benchmarked tools in the WES data, classifying approximately 90% of the samples. Yleaf, Y-LineageTracker, and pathPhynder can correctly classify most samples (88%) sequenced with third-generation HTS. As a result, Yleaf provides the best performance for applications that use WGS and WES. Overall, our study offers researchers with a guide that allows them to select the most appropriate tool to analyze the NRY region using both second- and third-generation HTS data., We would like to thank our colleagues from the Teide-HPC Supercomputing facility (http://teidehpc.iter.es/en), which was funded by INP-2011-0063-PCT-430000-ACT (INNPLANTA program) from the Spanish Ministry of Economy and Competitiveness, for their support. This research was funded by Ministerio de Ciencia e Innovación (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds ‘A way of making Europe’ from the European Union; Ministerio de Economía, Industria y Competitividad (CGL2017-89021-P, Agencia Estatal de Investigación [AEI]), co-financed by European Regional Development Funds ‘A way of making Europe’ from the European Union; Fundación CajaCanarias and Fundación Bancaria “La Caixa” (2018PATRI20); Cabildo Insular de Tenerife (CGIEU0000219140); the agreements OA17/008 and OA23/043 with Instituto Tecnológico y de Energías Renovables (ITER) to strengthen scientific and technological education, training, research, development and innovation in Genomics, epidemiological surveillance based on massive sequencing, Personalized Medicine and Biotechnology; the Basque Government, Basque Country Research Group (IT-1693-22); and the agreement between Consejería de Educación, Universidades, Cultura y Deportes and Cabildo Insular de Tenerife (AC0000014697). A.M.-B., L.A.R.-R. and J.M.L.-S. acknowledge the University of La Laguna for training support during their PhD studies. A.D.-d.U. was supported by a fellowship from the Spanish Ministry of Education and Vocational Training (grant number FPU16/01435)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Digging into the admixture strata of current-day Canary Islanders based on mitogenomes

  • García-Olivares, Víctor
  • Rubio-Rodríguez, Luis A.
  • Muñoz-Barrera, Adrián
  • Díaz-de Usera, Ana
  • Jáspez, David
  • Iñigo-Campos, Antonio
  • Rodríguez-Pérez, María del Cristo
  • Cabrera de León, Antonio
  • Lorenzo-Salazar, José M.
  • González-Montelongo, Rafaela
  • Cabrera, Vicente M.
  • Flores, Carlos
© 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., The conquest of the Canary Islands by Europeans began at the beginning of the 15th century and culminated in 1496 with the surrender of the aborigines. The collapse of the aboriginal population during the conquest and the arrival of settlers caused a drastic change in the demographic composition of the archipelago. To shed light on this historical process, we analyzed 896 mitogenomes of current inhabitants from the seven main islands. Our findings confirm the continuity of aboriginal maternal contributions and the persistence of their genetic footprints in the current population, even at higher levels (>60% on average) than previously evidenced. Moreover, the age estimates for most autochthonous founder lineages support a first aboriginal arrival to the islands at the beginning of the first millennium. We also revealed for the first time that the main recognizable genetic influences from Europe are from Portuguese and Galicians., This research was funded by Ministerio de Ciencia e Innovación (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds ‘A way of making Europe’ from the European Union; Fundación CajaCanarias and Fundación Bancaria “La Caixa” (2018PATRI20); Cabildo Insular de Tenerife (CGIEU0000219140); Convenio Marco de Cooperación Consejería de Educación-Cabildo Insular de Tenerife 2021–2025 (CGIAC0000014697); and by the agreement OA17/008 with Instituto Tecnológico y de Energías Renovables (ITER) to strengthen scientific and technological education, training, research, development, and innovation in Genomics, Personalized Medicine, and Biotechnology. A.D.U. was supported by a fellowship from the Spanish Ministry of Education and Vocational Training (grant number FPU16/01435). We would like to thank the support from our colleagues from the Teide-HPC Supercomputing facility (http://teidehpc.iter.es/en), which was funded by INP-2011-0063-PCT-430000-ACT (INNPLANTA program) from the Spanish Ministry of Economy and Competitiveness., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel risk loci for COVID-19 hospitalization among admixed American populations

  • Diz-de Almeida, Silvia
  • Cruz, Raquel
  • Luchessi, Andre D.
  • Lorenzo-Salazar, José M.
  • de Heredia, Miguel López
  • Quintela, Inés
  • González-Montelongo, Rafaela
  • Nogueira Silbiger, Vivian
  • Porras, Marta Sevilla
  • Tenorio Castaño, Jair Antonio
  • Nevado, Julian
  • Aguado, Jose María
  • Aguilar, Carlos
  • Aguilera-Albesa, Sergio
  • Almadana, Virginia
  • Almoguera, Berta
  • Alvarez, Nuria
  • Andreu-Bernabeu, Álvaro
  • Arana-Arri, Eunate
  • Arango, Celso
  • Arranz, María J
  • Artiga, Maria-Jesus
  • Baptista-Rosas, Raúl C.
  • Barreda-Sánchez, María
  • Belhassen-Garcia, Moncef
  • Bezerra, Joao F
  • Bezerra, Marcos A. C.
  • Boix-Palop, Lucía
  • Brion, María
  • Brugada, Ramón
  • Bustos, Matilde
  • Calderón, Enrique J.
  • Carbonell, Cristina
  • Castano, Luis
  • Castelao, Jose E
  • Conde-Vicente, Rosa
  • Cordero-Lorenzana, M. Lourdes
  • Cortes-Sanchez, Jose L.
  • Corton, Marta
  • Darnaude, M. Teresa
  • De Martino-Rodríguez, Alba
  • Del Campo-Pérez, Victor
  • de Bustamante, Aranzazu Diaz
  • Domínguez-Garrido, Elena
  • Eirós, Rocío
  • Fariñas, María del Carmen
  • Fernandez-Nestosa, María J.
  • Fernández-Robelo, Uxía
  • Fernández-Rodríguez, Amanda
  • Fernández-Villa, Tania
  • Gago-Dominguez, Manuela
  • Gil-Fournier, Belén
  • Gómez-Arrue, Javier
  • Álvarez, Beatriz González
  • Bernaldo de Quirós, Fernan Gonzalez
  • González-Neira, Anna
  • González-Peñas, Javier
  • Gutiérrez-Bautista, Juan F.
  • Herrero, María José
  • Herrero-Gonzalez, Antonio
  • Jimenez-Sousa, María A.
  • Lattig, María Claudia
  • Borja, Anabel Liger
  • López-Rodríguez, Rosario
  • Mancebo, Esther
  • Martín-López, Caridad
  • Martín, Vicente
  • Martinez-Nieto, Oscar
  • Martinez-López, Icíar
  • Martinez-Resendez, Michel F.
  • Martinez-Perez, Angel
  • Mazzeu, Juliana F.
  • Macías, Eleuterio Merayo
  • Minguez, Pablo
  • Cuerda, Victor Moreno
  • Oliveira, Silviene F.
  • Ortega-Paino, Eva
  • Parellada, Mara
  • Paz-Artal, Estela
  • Santos, Ney P. C.
  • Pérez-Matute, Patricia
  • Perez, Patricia
  • Pérez-Tomás, M Elena
  • Perucho, Teresa
  • Pinsach-Abuin, Mellina
  • Pita, Guillermo
  • Pompa-Mera, Ericka N.
  • Porras-Hurtado, Gloria L.
  • Pujol, Aurora
  • León, Soraya Ramiro
  • Resino, Salvador
  • Fernandes, Marianne R.
  • Rodríguez-Ruiz, Emilio
  • Rodríguez-Artalejo, Fernando
  • Rodriguez-Garcia, José A.
  • Ruiz-Cabello, Francisco
  • Ruiz-Hornillos, Javier
  • Ryan, Pablo
  • Soria, José Manuel
  • Souto, Juan Carlos
  • Tamayo, Eduardo
  • Tamayo-Velasco, Alvaro
  • Taracido-Fernandez, Juan Carlos
  • Teper, Alejandro
  • Torres-Tobar, Lilian
  • Urioste, Miguel
  • Valencia-Ramos, Juan
  • Yáñez, Zuleima
  • Zarate, Ruth
  • de Rojas, Itziar
  • Ruiz, Agustín
  • Sánchez, Pascual
  • Real, Luis Miguel
  • Guillen-Navarro, Encarna
  • Ayuso, Carmen
  • Parra, Esteban
  • Riancho, José A.
  • Rojas-Martinez, Augusto
  • Flores, Carlos
  • Lapunzina, Pablo
  • Carracedo, Ángel
The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific common risk loci. In this second study nested in the SCOURGE consortium, we conducted a genome-wide association study (GWAS) for COVID-19 hospitalization in admixed Americans, comprising a total of 4702 hospitalized cases recruited by SCOURGE and seven other participating studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide significant associations, two of which constitute novel loci and were first discovered in Latin American populations (BAZ2B and DDIAS). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in CREBBP. Finally, we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort. This study constitutes the largest GWAS for COVID-19 hospitalization in admixed Latin Americans conducted to date. This allowed to reveal novel risk loci and emphasize the need of considering the diversity of populations in genomic research., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modelling the demographic history of human North African genomes points to a recent soft split divergence between populations

  • Serradell, Jose M.
  • Lorenzo-Salazar, José M.
  • Flores, Carlos
  • Lao, Oscar
  • Comas, David
[Background] North African human populations present a complex demographic scenario due to the presence of an autochthonous genetic component and population substructure, plus extensive gene flow from the Middle East, Europe, and sub-Saharan Africa., [Results] We conducted a comprehensive analysis of 364 genomes to construct detailed demographic models for the North African region, encompassing its two primary ethnic groups, the Arab and Amazigh populations. This was achieved through an Approximate Bayesian Computation with Deep Learning (ABC-DL) framework and a novel algorithm called Genetic Programming for Population Genetics (GP4PG). This innovative approach enabled us to effectively model intricate demographic scenarios, utilizing a subset of 16 whole genomes at > 30X coverage. The demographic model suggested by GP4PG exhibited a closer alignment with the observed data compared to the ABC-DL model. Both point to a back-to-Africa origin of North African individuals and a close relationship with Eurasian populations. Results support different origins for Amazigh and Arab populations, with Amazigh populations originating back in Epipaleolithic times, while GP4PG supports Arabization as the main source of Middle Eastern ancestry. The GP4PG model includes population substructure in surrounding populations (sub-Saharan Africa and Middle East) with continuous decaying gene flow after population split. Contrary to ABC-DL, the best GP4PG model does not require pulses of admixture from surrounding populations into North Africa pointing to soft splits as drivers of divergence in North Africa., [Conclusions] We have built a demographic model on North Africa that points to a back-to-Africa expansion and a differential origin between Arab and Amazigh populations., This work was supported by the Spanish Ministry of Science and Innovation and by “ERF A way of making Europe” (grant numbers RTC-2017–6471–1 AEI/FEDER, UE, PID2019-106485 GB-I00, and PID2022-138755NB-I00), Fundación CajaCanarias and Fundación Bancaria “La Caixa” (2018PATRI20), and “Unidad María de Maeztu” (CEX2018-000792-M) funded by the MCIN and the AEI (https://doi.org/10.13039/501100011033). J.M.S was supported with a Formació de Personal Investigador fellowship from Generalitat de Catalunya (FI_B100135)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000792-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia

  • García-García, Ana
  • Pérez de Diego, Rebeca
  • Flores, Carlos
  • Rinchai, Darawan
  • Solé-Violán, Jordi
  • Deyà-Martínez, Àngela
  • García-Solis, Blanca
  • Lorenzo-Salazar, José M.
  • Hernández-Brito, Elisa
  • Lanz, Anna-Lisa
  • Moens, Leen
  • Bucciol, Giorgia
  • Almuqamam, Mohamed
  • Domachowske, Joseph B.
  • Colino, Elena
  • Santos-Perez, Juan Luis
  • Marco, Francisco M.
  • Pignata, Claudio
  • Bousfiha, Aziz
  • Turvey, Stuart E.
  • Bauer, Stefanie
  • Haerynck, Filomeen
  • Ocejo-Vinyals, Javier Gonzalo
  • Lendinez, Francisco
  • Prader, Seraina
  • Naumann-Bartsch, Nora
  • Pachlopnik Schmid, Jana
  • Biggs, Catherine M.
  • Hildebrand, Kyla
  • Dreesman, Alexandra
  • Cárdenes, Miguel Ángel
  • Ailal, Fatima
  • Benhsaien, Ibtihal
  • Giardino, Giuliana
  • Molina-Fuentes, Agueda
  • Fortuny, Claudia
  • Madhavarapu, Swetha
  • Conway, Daniel H.
  • Prando, Carolina
  • Schidlowski, Laire
  • Martínez de Saavedra Álvarez, María Teresa
  • Alfaro, Rafael
  • Rodríguez de Castro, Felipe
  • Meyts, Isabelle
  • Hauck, Fabian
  • Puel, Anne
  • Bastard, Paul
  • Boisson, Bertrand
  • Jouanguy, Emmanuelle
  • Abel, Laurent
  • Cobat, Aurélie
  • Zhang, Qian
  • Casanova, Jean-Laurent
  • Alsina, Laia
  • Rodríguez-Gallego, Carlos
X-linked recessive deficiency of TLR7, a MyD88- and IRAK-4-dependent endosomal ssRNA sensor, impairs SARS-CoV-2 recognition and type I IFN production in plasmacytoid dendritic cells (pDCs), thereby underlying hypoxemic COVID-19 pneumonia with high penetrance. We report 22 unvaccinated patients with autosomal recessive MyD88 or IRAK-4 deficiency infected with SARS-CoV-2 (mean age: 10.9 yr; 2 mo to 24 yr), originating from 17 kindreds from eight countries on three continents. 16 patients were hospitalized: six with moderate, four with severe, and six with critical pneumonia, one of whom died. The risk of hypoxemic pneumonia increased with age. The risk of invasive mechanical ventilation was also much greater than in age-matched controls from the general population (OR: 74.7, 95% CI: 26.8-207.8, P < 0.001). The patients' susceptibility to SARS-CoV-2 can be attributed to impaired TLR7-dependent type I IFN production by pDCs, which do not sense SARS-CoV-2 correctly. Patients with inherited MyD88 or IRAK-4 deficiency were long thought to be selectively vulnerable to pyogenic bacteria, but also have a high risk of hypoxemic COVID-19 pneumonia., The study was funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, PI16/00759, PI18/00223, PI19/ 00208, PI20/00876, and PI21/00211), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43 and FIISC22/27), Grupo DISA (OA18/017 and OA22/035), Fundación MAPFRE Guanarteme (OA21/131), Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas cient´ıficas del ITER para colaborar en la lucha contra la COVID- 19”), a 2022 Convocat`oria de Beques de Recerca IRSJD—Carmen de Torres 2022 (2022AR-IRSJD-CdTorres), CERCA Programme/ Generalitat de Catalunya, the Else Kr¨oner-Fresenius Stiftung (EKFS, 2017_A110), the German Federal Ministry of Education and Research (01GM1910C), the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the Horizon Europe Framework Programme of the European Union under Grant Agreement no. 101057100. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

  • Asano, Takaki
  • Boisson, Bertrand
  • Onodi, Fanny
  • Matuozzo, Daniela
  • Moncada-Velez, Marcela
  • Maglorius Renkilaraj, Majistor Raj Luxman
  • Zhang, Peng
  • Meertens, Laurent
  • Bolze, Alexandre
  • Materna, Marie
  • Korniotis, Sarantis
  • Gervais, Adrian
  • Talouarn, Estelle
  • Bigio, Benedetta
  • Seeleuthner, Yoann
  • Bilguvar, Kaya
  • Zhang, Yu
  • Neehus, Anna-Lena
  • Ogishi, Masato
  • Pelham, Simon J.
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Soler-Palacín, Pere
  • Colobran, Roger
  • Martin-Nalda, Andrea
  • Rivière, Jacques G.
  • Tandjaoui-Lambiotte, Yacine
  • Chaïbi, Khalil
  • Shahrooei, Mohammad
  • Darazam, Ilad Alavi
  • Olyaei, Nasrin Alipour
  • Mansouri, Davood
  • Hatipoğlu, Nevin
  • Palabiyik, Figen
  • Ozcelik, Tayfun
  • Novelli, Giuseppe
  • Novelli, Antonio
  • Casari, Giorgio
  • Aiuti, Alessandro
  • Carrera, Paola
  • Bondesan, Simone
  • Barzaghi, Federica
  • Rovere-Querini, Patrizia
  • Tresoldi, Cristina
  • Franco, Jose Luis
  • Rojas, Julian
  • Reyes, Luis Felipe
  • Bustos, Ingrid G.
  • Arias, Andres Augusto
  • Morelle, Guillaume
  • Christèle, Kyheng
  • Troya, Jesús
  • Planas-Serra, Laura
  • Schlüter, Agatha
  • Gut, Marta
  • Pujol, Aurora
  • Allende, Luis M.
  • Rodriguez-Gallego, Carlos
  • Flores, Carlos
  • Cabrera-Marante, Oscar
  • Pleguezuelo, Daniel E.
  • Pérez de Diego, Rebeca
  • Keles, Sevgi
  • Aytekin, Gokhan
  • Akcan, Ozge Metin
  • Bryceson, Yenan T.
  • Bergman, Peter
  • Brodin, Petter
  • Smole, Daniel
  • Smith, C. I. Edvard
  • Norlin, Anna-Carin
  • Campbell, Tessa M.
  • Covill, Laura E.
  • Hammarström, Lennart
  • Pan-Hammarström, Qiang
  • Abolhassani, Hassan
  • Mane, Shrikant
  • Marr, Nico
  • Ata, Manar
  • Al Ali, Fatima
  • Khan, Taushif
  • Spaan, András N.
  • Dalgard, Clifton L.
  • Bonfanti, Paolo
  • Biondi, Andrea
  • Tubiana, Sarah
  • Burdet, Charles
  • Nussbaum, Robert
  • Kahn-Kirby, Amanda
  • Snow, Andrew L.
  • Bustamante, Jacinta
  • Puel, Anne
  • Boisson-Dupuis, Stéphanie
  • Zhang, Shen-Ying
  • Béziat, Vivien
  • Lifton, Richard P.
  • Bastard, Paul
  • Notarangelo, Luigi D.
  • Abel, Laurent
  • Su, Helen C.
  • Jouanguy, Emmanuelle
  • Amara, Ali
  • Soumelis, Vassili
  • Cobat, Aurélie
  • Zhang, Qian
  • Casanova, Jean-Laurent
Members of COVID Human Genetic Effort: Laurent Abel1, Alessandro Aiuti2, Saleh Al-Muhsen3, Fahd Al-Mulla4, Mark S. Anderson5, Evangelos Andreakos6, Andrés A. Arias7, Hagit Baris Feldman8, Alexandre Belot9, Catherine M. Biggs10, Dusan Bogunovic11, Alexandre Bolze12, Anastasiia Bondarenko13, Ahmed A. Bousfiha14, Petter Brodin15, Yenan Bryceson16, Carlos D. Bustamante17, Manish J. Butte18, Giorgio Casari19, Samya Chakravorty20, John Christodoulou21, Antonio Condino-Neto22, Stefan N. Constantinescu23, Megan A. Cooper24, Clifton L. Dalgard25, Murkesh Desai26, Beth A. Drolet27, Jamila El Baghdadi28, Sara Espinosa-Padilla29, Jacques Fellay30, Carlos Flores31, José Luis Franco7, Antoine Froidure32, Peter K. Gregersen33, Filomeen Haerynck34, David Hagin35, Rabih Halwani36, Lennart Hammarström37, James R. Heath38, Sarah E. Henrickson39, Elena W. Y. Hsieh40, Eystein Husebye41, Kohsuke Imai42, Yuval Itan43, Erich D. Jarvis44, Timokratis Karamitros45, Kai Kisand46, Cheng-Lung Ku47, Yu-Lung Lau48, Yun Ling49, Carrie L. Lucas50, Tom Maniatis51, Davood Mansouri52, László Maródi53, Isabelle Meyts54, Joshua D. Milner55, Kristina Mironska56, Trine H. Mogensen57, Tomohiro Morio58, Lisa F. P. Ng59, Luigi D. Notarangelo60, Antonio Novelli61, Giuseppe Novelli62, Cliona O’Farrelly63, Satoshi Okada64, Tayfun Ozcelik65, Qiang Pan-Hammarström37, Rebeca Perez de Diego66, Anna M. Planas67, Carolina Prando68, Aurora Pujol69, Lluis Quintana-Murci70, Laurent Renia59, Igor Resnick71, Carlos Rodríguez-Gallego72, Vanessa Sancho-Shimizu73, Anna Sediva74, Mikko R. J. Seppänen75, Mohammed Shahrooei76, Anna Shcherbina77, Ondrej Slaby78, Andrew L. Snow79, Pere Soler-Palacín80, András N. Spaan81, Ivan Tancevski82, Stuart G. Tangye83, Ahmad Abou Tayoun84, Sathishkumar Ramaswamy84, Stuart E. Turvey85, Furkan Uddin86, Mohammed J. Uddin87, Diederik van de Beek88, Donald C. Vinh89, Horst von Bernuth90, Mayana Zatz91, Pawel Zawadzki92, Helen C. Su60, Jean-Laurent Casanova93, Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10-5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4 We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7 The patients' blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, Rockefeller University; the St. Giles Foundation; the NIH (R01AI088364), the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866); a Fast Grant from Emergent Ventures; Mercatus Center at the George Mason University; the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956); the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01) and the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (EQU201903007798); the FRM and ANR GENCOVID project, the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AABIFNCOV (ANR-20-CO11-0001) projects; the European Union’s Horizon 2020 Research and Innovation Program under grant agreement no. 824110 (EASI-genomics); the Square Foundation; Grandir–Fonds de solidarité pour l’enfance; the SCOR Corporate Foundation for Science; Fondation du Souffle; Institut National de la Santé et de la Recherche Médicale (INSERM); REACTing-INSERM; and the University of Paris. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). The Neurometabolic Diseases Laboratory received funding from the European Union’s Horizon 2020 Research and Innovation Program (EasiGenomics grant no. 824110 COVID-19/PID12342). A.P., R.P.d.D., C.R.-G., and C.F. were funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación DISA (OA18/017), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The laboratories of G.N. and A.N. were supported by a grant awarded to Regione Lazio (PROGETTI DI GRUPPI DI RICERCA 2020) no. A0375-2020-36663, GecoBiomark. A. Amara’s laboratory was supported by ANR under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the FRM (EQU202003010193), ANR (ANR-20-COVI-000 project IDISCOVR and ANR-20-CO11-0004 project FISHBP), and the University of Paris (Plan de Soutien Covid-19: RACPL20FIR01-COVIDSOUL). This work was supported, in part, by the Division of Intramural Research, NIAID, NIH (grants 1ZIAAI001265 to H.C.S. and ZIA AI001270 to L.D.N.). The G.C. laboratory was supported by the Italian Ministry of Health (grant COVID-2020-12371617) and the intramural COVID Host Genetics program. The J.L.F. laboratory was supported, in part, by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX; 806-2018) and Colciencias contract 713-2016 (no. 111574455633). The V.S. laboratory was supported by ANR DENDRISEPSIS (ANR-17-CE15-0003) and ANR APCOD (ANR-17-CE15-0003-01), a Fast Grant from the Mercatus Center, FRM, University of Paris PLAN D’URGENCE COVID19. The N.M. laboratory was supported by Sidra Medicine (SDR400048) and the Qatar National Research Fund (grant No. NPRP9-251-3-045). A.-L.N. was supported by the Bettencourt Schueller Foundation and the International PhD program of the Imagine Institute. P. Bergman and C.I.E.S received support from the Center for Medical Innovation (CIMED), the Swedish Medical Research Council and the Stockholm County Council (ALF-project). Part of this work was generated within the European Reference Network for rare primary immunodeficiency, autoinflammatory and autoimmune diseases (RITA). Author contributions: A.K.-K., A. Amara, A.C., A.G., A.-L.N., A. Puel, B. Boisson, E.J., F.A.A., F.O., J.B., J. Rosain, L.M., M.A., M.M.-V., M.M., M.O., M.R.L.M.R., N.M., P. Bastard, Q.P., Q.Z., S.B.-D., S.J.P., S. Korniotis, S.M., T.A., T.K., T.L.V., V.B., V.S., P.Z., S.-Y.Z., and Y.Z. performed or supervised experiments, generated and analyzed data, and contributed to the manuscript by providing figures and tables. A.C., A. Bolze, A. Pujol, B. Bigio, D. Matuozzo, K.B., L.A., and Y.S. performed computational analyses of data. A. Aiuti, A.A.A., A. Biondi, A.-C.N., A.L.S., A.M.-N., A.N., A.N.S., A.S., A. Pujol, C.B., C.F., C.K., C.L.D., C.T., D.E.P., D. Mansouri, D.S., E.J., C.I.E.S., F.B., F.P., G.A., G.C., G.M., G.N., H.A., H.C.S., I.A.D., I.G.B., J.C.R.G., J.G.R., J.L.F., J. Rojas, J.T., K.C., L.F.R., L.E.C., L.H., L.D.N., L.P.-S., M.G., L.M.A., M.S., N.A.O., N.H., O.C.-M., O.M.A., P. Bergman, P. Brodin, P.C., P.R.-Q., P.S.-P., P. Bastard, P. Bonfanti, Q.P.-H., Q.Z., R.C., R.N., R.P.d.D., R.P.L., S.A., S.B., S.T., S. Keles, T.M.C., T.O., Y.T.B., and Y.T.-L. evaluated and recruited patients to the COVID and/or control cohorts. B. Boisson, Q.Z., A.C., L.A. and J.-L.C. wrote the manuscript. All the authors edited the manuscript. J.-L.C. supervised the project, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Diagnostic and prognostic implications of family history of fibrotic interstitial lung diseases

  • Duminy-Luppi, D.
  • Alcaide-Aldeano, A.
  • Planas-Cerezales, Lurdes
  • Bermudo, G.
  • Vicens-Zygmunt, Vanesa
  • Luburich Hernaiz, Patricio
  • Río-Carrero, B. Del
  • Llatjós Sanuy, Roger
  • Pijuan,L.
  • Escobar, I.
  • Rivas, F.
  • Montes-Worboys, Ana
  • Gutiérrez-Rodríguez, Y.
  • Rodríguez-Plaza, D.
  • Padró-Miquel, A.
  • Esteve-García, A.
  • Fernández-Varas, Beatriz
  • Flores, Claudio
  • Fuentes, M.
  • Dorca Sargatal, Jordi
  • Santos, S.
  • Perona Abellón, Rosario
  • Günther, A.
  • Shull, J.
  • Molina-Molina, María
[Background]: Patients with familial fibrotic interstitial lung disease (ILD) experience worse survival than patients with sporadic disease. Current guidelines do not consider family aggregation or genetic information in the diagnostic algorithm for idiopathic pulmonary fibrosis or other fibrotic ILDs. Better characterizing familial cases could help in diagnostic and treatment decision-making., [Methods]: This retrospective cohort study included 222 patients with fibrotic ILD (104 familial and 118 sporadic) from Bellvitge University Hospital. Clinical, radiological, pulmonary functional tests (PFT), and histological evaluations were performed at diagnosis and follow-up. Telomere shortening and disease-associated variants (DAVs) in telomerase-related genes were analysed in familial patients and sporadic patients with telomeric clinical signs. Primary outcomes were the presence of a UIP histological pattern and disease progression., [Results]: Patients with idiopathic pulmonary fibrosis (IPF) (52%), fibrotic hypersensitivity pneumonitis (23%), and other fibrotic ILDs (25%) were included. 42% of patients underwent lung biopsy. Patients with family aggregation were younger and less frequently associated comorbidities, male sex, and smoking history. However, usual interstitial pneumonia (UIP) was more frequent on pathology (p = 0.005; OR 3.37), especially in patients with indeterminate or non-UIP radiological patterns. Despite similar PFT results at diagnosis, familial patients were more likely to present with progressive disease (p = 0.001; OR 3.75). Carrying a DAV increased the risk of fibrotic progression in familial and sporadic patients (p = 0.029, OR 5.01)., [Discussion]: Familial patients diagnosed with different fibrotic ILDs were more likely to exhibit a histological UIP pattern and disease progression than sporadic patients, independent of radiological findings and pulmonary function at diagnosis., [Conclusion]: Considering the diagnostic likelihood of the histological UIP pattern and disease outcome, the presence of family aggregation would be useful in the decision making of multidisciplinary committees., Part of this study was funded by Instituto de Salud Carlos III and the European Joint Programme on Rare Diseases (EJP RD) (AC19/00006), Ministerio de Ciencia e Innovación (grant RTC-2017-6471-1; AEI/FEDER, UE), the agreements with Instituto Tecnológico y de Energías Renovables to strengthen scientific and technological education, training, research, development and innovation in genomics, epidemiological surveillance based on massive sequencing, Personalized Medicine and Biotechnology (OA17/008 and OA23/043), Cabildo Insular de Tenerife (CGIEU0000219140), and the funds of Boehringer Ingelheim through Fundación Catalana de Pneumologia (FUCAP). IDIBELL receives funding from the CERCA Program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A tiered strategy to identify relevant genetic variants in familial pulmonary fibrosis: a proof of concept for the clinical practice

  • Alonso-González, Aitana
  • Véliz-Flores, Ibrahim
  • Tosco-Herrera, Eva
  • González-Barbuzano, Silvia
  • Mendoza-Alvarez, Alejandro
  • Galván-Fernández, Helena
  • Sastre, Leandro
  • Fernández-Varas, Beatriz
  • Corrales, Almudena
  • Rubio-Rodríguez, Luis A.
  • Jáspez, David
  • Lorenzo-Salazar, José M.
  • Molina-Molina, María
  • Rodríguez-de-Castro, Felipe
  • González-Montelongo, Rafaela
  • Flores, Carlos
Idiopathic pulmonary fibrosis (IPF) is a progressive, late-onset disease marked by lung scarring and irreversible loss of lung function. Genetic factors significantly contribute to both familial and sporadic cases, yet there are scarce evidence-based studies highlighting the benefits of integrating genetics into the management of IPF patients. In this study, we performed whole-exome sequencing and telomere length (TL) measurements on IPF patients and their relatives. We then identified rare deleterious variants using three virtual gene panels encompassing IPF or TL genes with varying levels of evidence supporting their potential relationship with the disease. We identified 10 candidate variants in well-established disease genes, and these results were validated using two automatic prioritization tools (Exomiser and Franklin). Pathogenic variants were found in two telomere-related genes (RTEL1 and NAF1), and both were associated with severe TL shortening. Our results suggest that this tiered virtual panel strategy is sufficiently robust and serves as a viable solution in clinical practice. It generates valuable genetic data which can be interpreted and validated with the expertise of a multidisciplinary team., This research was funded by Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER), Instituto de Salud Carlos III (CB06/06/1088, PMP22/00083, and PI23/00980) and co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union; the agreements OA17/008 and OA23/043 with Instituto Tecnológico y de Energías Renovables (ITER) to strengthen scientific and technological education, training, research, development and scientific innovation in genomics, epidemiological surveillance based on massive sequencing, personalized medicine, and biotechnology; by Cabildo Insular de Tenerife (CGIEU0000219140), by Asociación Canaria de Neumología y Cirugía Torácica (NEUMOCAN) and by Research Grant from the Illustrious Medical College of Las Palmas de Gran Canarias 2022. AA-G is beneficiary of a Margarita Salas contract funded by the Program for requalification, international mobility and talent attraction in the Spanish university system (grant UP2021-042) and ET-H was supported by a fellowship from Agencia Canaria de Investigación, Innovación y Sociedad de la Información del Gobierno de Canarias (TESIS2021010046). JML-S was supported by Cabildo Insular de Tenerife and Consejería de Educación, Gobierno de Canarias (A0000014697)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

  • Bastard, Paul|||0000-0002-5926-8437
  • Rosen, Lindsey|||0000-0001-5894-3878
  • Zhang, Qian|||0000-0002-9040-3289
  • Michailidis, Eleftherios|||0000-0002-9907-4346
  • Hoffmann, Hans-Heinrich|||0000-0003-0554-0244
  • Zhang, Yu|||0000-0002-0332-0013
  • Dorgham, Karim|||0000-0001-9539-3203
  • Philippot, Quentin
  • Rosain, Jérémie|||0000-0002-2822-161X
  • Béziat, Vivien|||0000-0002-4020-824X
  • Manry, Jeremy|||0000-0001-5998-2051
  • Shaw, Elana|||0000-0001-9265-8026
  • Haljasmägi, Liis|||0000-0001-7162-9808
  • Peterson, Pärt|||0000-0001-6755-791X
  • Lorenzo, Lazaro|||0000-0001-6648-8684
  • Bizien, Lucy|||0000-0001-9163-9122
  • Trouillet-Assant, Sophie|||0000-0001-6439-4705
  • Dobbs, Kerry|||0000-0002-3432-3137
  • Almeida de Jesus, Adriana
  • Belot, Alexandre|||0000-0003-4902-5332
  • Kallaste, Anne|||0000-0002-7492-667X
  • Catherinot, Emilie
  • Tandjaoui-Lambiotte redondo, Yacine|||0000-0003-1123-4788
  • Le Pen, Jérémie|||0000-0001-7025-9526
  • Kerner, Gaspard|||0000-0003-0146-9428
  • Bigio, Benedetta|||0000-0001-7291-5638
  • Seeleuthner, Yoann|||0000-0002-1878-8567
  • Yang, Rui|||0000-0003-4427-2158
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Spaan, András|||0000-0001-5981-7259
  • Delmonte, Ottavia M.
  • Abers, Michael S.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Casari, Giorgio|||0000-0002-0115-8980
  • Lampasona, Vito|||0000-0001-5162-8445
  • Piemonti, Lorenzo|||0000-0002-2172-2198
  • Ciceri, Fabio|||0000-0003-0873-0123
  • Bilguvar, Kaya|||0000-0002-7313-7652
  • Lifton, Richard P.
  • Vasse, Marc
  • Smadja, David M.
  • Migaud, Mélanie|||0000-0003-3062-1214
  • Hadjadj, Jérome|||0000-0002-2520-3272
  • Terrier, Benjamin|||0000-0001-6612-7336
  • Duffy, Darragh|||0000-0002-8875-2308
  • Quintana-Murci, Lluis|||0000-0003-2429-6320
  • van de Beek, Diederik|||0000-0002-4571-044X
  • Roussel, Lucie|||0000-0001-5355-702X
  • Vinh, Donald C.|||0000-0003-1347-7767
  • Tangye, Stuart|||0000-0002-5360-5180
  • Haerynck, Filomeen|||0000-0001-9161-7361
  • Dalmau, David|||0000-0003-1936-478X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Brodin, Petter|||0000-0002-8103-0046
  • Nussenzweig, Michel|||0000-0003-0592-8564
  • Boisson-Dupuis, Stephanie|||0000-0002-7115-116X
  • Rodríguez-Gallego, Carlos|||0000-0002-4344-8644
  • Vogt, Guillaume
  • Mogensen, Trine Hyrup|||0000-0002-1853-9704
  • Oler, Andrew J.|||0000-0002-6310-0434
  • Gu, Jingwen
  • Burbelo, Peter D.|||0000-0003-1717-048X
  • Cohen, Jeffrey I.|||0000-0003-0238-7176
  • Biondi, Andrea
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Rossignol, Patrick
  • Mayaux, Julien
  • Rieux-Laucat, Frédéric|||0000-0001-7858-7866
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Fusco, Francesca
  • Ursini, Matilde Valeria
  • Imberti, Luisa|||0000-0002-2075-8391
  • Sottini, Alessandra
  • Paghera, Simone
  • Quiros-Roldan, Eugenia
  • Rossi, Camillo
  • Castagnoli, Riccardo|||0000-0003-0029-9383
  • Montagna, Daniela
  • Licari, Amelia|||0000-0002-1773-6482
  • Marseglia, Gian Luigi|||0000-0003-3662-0159
  • Duval, Xavier
  • Ghosn, Jade
  • Tsang, John S.|||0000-0003-3186-3047
  • Goldbach-Mansky, Raphaela|||0000-0001-7865-5769
  • Kisand, Kai|||0000-0002-5426-4648
  • Lionakis, Michail S.
  • Puel, Anne|||0000-0003-2603-0323
  • Zhang, Shein-Ying
  • Holland, Steven|||0000-0003-3207-5464
  • Gorochov, Guy|||0000-0003-2097-9677
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Rice, Charles M.|||0000-0003-3087-8079
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Notarangelo, Luigi|||0000-0002-8335-0262
  • Abel, Laurent|||0000-0001-7016-6493
  • Su, Helen C.|||0000-0002-5582-9110
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.